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CHAPTER -1 
INTRODUCTION 
Oral drug has been known for decades as the most widely utilized route of administration 
among all the routes that have been explored for the systemic delivery of drug via various 
pharmaceutical products of different dosage form. The reason that oral route achieved such 
popularity may be attributed to its ease of administration as well as the traditional belief that 
by oral administration the drug is well absorbed as the food stuff  ingested  daily.1 The oral 
route of drug administration has been  used for both conventional as well as novel drug 
delivery system. The reasons for this preference are obvious because of the ease of 
administration and widespread acceptance by patients. The common oral dosage forms 
include: solid dosage forms like tablets and capsules, etc and liquid dosage forms like 
mixture, syrup, solution, suspension, emulsion etc. Compared to other oral dosage forms, 
tablets are manufacturers, choice because of their relatively low cost of manufacture, package 
and shipment; increased stability and virtual tamper resistance.2 Among the oral dosage 
forms, tablets of various types are most used, because it is convenient and safe way of 
administration. In addition it has advantage in terms of the chemical and physical stability as 
well as accurate dosing of drug over other dosage forms.3 
1. TABLETS 
“It is a solid oral dosage form containing a unit dose of one or more medicaments.” Tablet 
may be defined as solid pharmaceutical dosage form containing drug substance with or 
without suitable diluents and prepared either by compression (or) molding methods.4 They are 
most widely preferred form of medication both by pharmaceutical manufacturer as well as 
physicians and patients. They offer safe and convenient ways of active pharmaceutical 
ingredients (API) administration with excellent physiochemical stability in comparison to 
some other dosage forms and provide accurate dosing. Tablets are usually solid, right circular 
cylinders, the end surfaces of which are flat or convex and the edges of which may bevelled.5 
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1.1 Ideal properties of tablets6 
The attributes of an acceptable tablet are as follows: 
 The tablets must be sufficiently strong and resistance to shock and abrasion and 
withstand handling during manufacturing, packing and shipping.  
 Tablet must be uniform in weight and drug content. 
 The drug must be bioavailable. Accurate bioavailability can be obtained from the drug 
levels after its administration. 
 Tablets must be elegant in appearance and must have characteristic shape, color and 
other markings necessary to identify the product. 
 Tablets must retain all these function attributes, which include drug stability and 
efficacy. 
 1.1.1 Advantages of tablets7 
 They are easy to administer. 
 They are unit dosage form and they offer the greater capable of all oral dosage forms for 
the greatest dose precision and the least content variability. 
 Their cost is lowest of all oral dosage forms. 
 Product identification is potentially the simplest and cheapest, requiring no additional 
processing steps when employing an embossed or monogrammed punch face. 
 Suitable for large scale production. 
 They lend themselves to certain special release profile products, such as enteric or 
delayed release products. 
 One of major advantages of tablet over capsule is that the tablet is essentially “tamper 
proof dosage form”. 
 They have the best combined properties of chemical, mechanical and microbiological 
stability of all the oral dosage forms. 
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1.1.2 Disadvantages of tablets: 
 Some drugs resist compression into dense compacts, owing to their amorphous nature or 
flocculent, low density character. 
 Drugs with poor wetting, slow dissolution properties, intermediate to large dosages, poor 
absorption in the gastrointestinal tract or any combination of these features may be 
difficult or impossible to formulate and manufacture as a tablet. 
 Difficult to swallow in case of children and unconscious patients. 
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1.2. TYPES OF TABLETS8: 
Tablets may be uncoated or coated. Uncoated tablets are chewable tablet, effervescent tablet, 
lozenge tablet, soluble tablet and sublingual tablet. Coated tablets are enteric coated tablet, 
film coated tablet, implant, sugar coated tablet and modified-release tablet. A broken section 
of a coated tablet shows a core which is surrounded by a continuous layer of a different 
texture. The reasons for coating a tablet are: 
a) to protect  the active ingredients from air, moisture and light. 
b) to mask the unpleasant tastes and odor; and 
c) to improve the appearance. 
A. Chewable tablet  
The tablet which is intended to be broken and chewed in between the teeth before ingestion. 
Antacid and vitamin tablets are usually prepared as chewable tablets. It is given to the 
children who have difficulty in swallowing and to the adults who dislike swallowing. 
B. Effervescent tablet 
The tablet that contains acid substances and carbonate or hydrogen carbonate that react 
rapidly in the presence of water to release carbon dioxide. Sodium bicarbonate, citric acid and 
tartaric acid are added to the active ingredients to make the tablet effervescent. This 
preparation makes the tablet palatable. 
C. Lozenge tablet 
The tablet that is intended to produce continuous effect on the mucous membrane of the 
throat. There is no disintegrating agent. The quality of the binding agent is increased so as to 
produce slow dissolution. Suitable sweetening (sugar), coloring and flavoring agents must be 
included in this formulation. Gum is used to give strength and cohesiveness to the lozenge 
and facilitating slow release of the active ingredient. 
D. Soluble tablet 
The tablet that dissolves completely in liquid to produce solution of definite concentration. 
Mouth wash, gargle, skin lotion, douche; antibiotic, certain vitamins and aspirin are given in 
this formulation. 
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E. Sublingual tablet 
The drug which is destroyed or inactivated within the gastrointestinal tract but can be 
absorbed through the mucosal tissue of the oral cavity is usually given in this formulation. 
The tablet is required to be placed below the tongue for the slow release of drug. But for 
immediate effect some medicaments are formulated in such a way to dissolve within 1 to 2 
minutes. Nitroglycerin is prepared as sublingual tablet. 
F. Enteric coated tablet 
Some drugs are destroyed by gastric juice or causes irritation to the stomach. These two 
factors can be overcome by coating the tablet with cellulose acetate phthalate. This polymer 
is insoluble in gastric contents but readily dissolves in intestinal contents. So there is a delay 
in the disintegration of dosage form until it reaches the small intestine.  
 Like coated tablet, enteric coated tablet should be administered in whole form. Broken or 
crushed form of the enteric coated tablet causes destruction of the drug by gastric juice or 
produce irritation to the stomach. Enteric coated tablet is comparatively expensive. 
G. Film coated tablet 
The tablet that is covered with a thin layer or film of polymeric substance which protects the 
drug from atmospheric conditions and mask the objectionable taste and the odor of drug. 
H. Implant tablet 
A small tablet that is prepared for insertion under the skin by giving a small surgical cut into 
the skin which is stitched after the insertion of the tablet. This tablet must be sterile. The drug 
used in this preparation is usually water insoluble and the tablet provides a slow and 
continuous release of drug over prolonged period of time ranging from 3 to 6 months or even 
more. Contraceptive tablet is formulated as implant. 
I. Sugar coated tablet 
The tablet that contains active ingredient(s) of unpleasant taste may be covered with sugar to 
make it more palatable. This type of tablet should be administered in whole form; otherwise 
the patient will experience the unpleasant taste of the active ingredient. 
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J. Modified release tablet 
Modified-release tablet is either uncoated or coated. This contains special additives or 
prepared by special procedure which, separately or together, is intended to modify the rate of 
release of the drug into the gastrointestinal tract. It prolongs the effect of drug and also 
reduces the frequency of administration of drug. Several drugs are available in modified 
release tablet form such as Indomethacin. 
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1.3 PHARMACEUTICAL EXCIPIENTS USED IN THE 
FORMULATION OF THE TABLETS 9 
Excipients are pharmacologically inactive substances which are added to the tablet 
formulation for the following purpose. 
 Provide bulk to the formulation.  
 Facilitate drug absorption or solubility and other pharmacokinetic considerations.  
  Aid in handling of “API” during manufacturing.  
 Provide stability and prevent from denaturation. 
 
1.3.1 Classification of Excipients for Solid Dosage Form10 
 
Additives are usually classified according to some primary function they perform in the 
pharmaceutical dosage form.  Many additives will also often have secondary functions, which 
may not be of a beneficial nature. The most effective lubricants used are water repellent by 
their nature, which may retard both disintegration and dissolution.  The two major 
classifications of additives by function include those which affect the compression 
charteristics of the pharmaceutical dosage form.  
A. Fillers and Diluents 
B. Binders and Adhesives 
C. Disintegrants 
D. Glidants 
E. Lubricants 
F. Antiadherents 
And those which affect the bio pharmaceutics, chemical and physical stability and marketing 
consideration of the pharmaceutical dosage form: 
G. Colours 
H. Flavours 
I. Sweeteners 
J. Preservatives 
K. Sorbents 
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A. Fillers : 
Fillers fill out the size of a tablet or capsule, making it practical to produce and convenient for 
the consumer to use. By increasing the bulk volume, the fillers make it possible for the final 
product to have the proper volume for patient handling. Good filler must be inert, compatible 
with the other components of the formulation, non-hygroscopic, soluble, relatively cheap, 
compactable and preferably tasteless or pleasant tasting. Dibasic calcium phosphate is 
popular tablet filler.  
Eg:  Lactose, sucrose, glucose, mannitol, sorbitol, calcium carbonate and magnesium 
stearate. 
 
B. Binders: 
Binders hold the ingredients in a tablet together. Binders ensure that tablets and granules can 
be formed with required mechanical strength and give volume to low active dose tablets.   
Eg: Sugars, cellulose or modified cellulose such as microcrystalline cellulose, hydroxypropyl 
cellulose, gelatin, polyvinyl pyrolidone, sodium alginate, acacia etc.  
 
C.  Disintegrants: 
Disintegrants expand and dissolve when wet, causing the tablet to break apart in the digestive 
tract and release the active ingredients for absorption. Disintegrants types include: 
 Water uptake facilitators 
 Tablet rupture promoters 
They ensure that when the tablet is in contact with water, it rapidly breaks down into smaller 
fragments, thereby facilitating dissolution.  
Eg: Cross linked polyvinylpyrrolidone, sodium starch glycolate, cross linked sodium 
carboxymethyl cellulose. 
 
D. Glidants: 
Glidants are used to promote powder flow by reducing interparticle friction and cohesion. 
These are used in combination with lubricants as they have no ability to reduce die wall 
friction.  
Eg:  Colloidal silicon dioxide, talc, etc. 
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E.  Lubricants: 
Lubricants prevent ingredients from clumping together and from sticking to the tablet 
punches or capsule filling machine. Lubricants also ensure that tablet formation and ejection 
can occur with low friction between the solid and die wall. 
Eg: Common minerals like talc or silica and fats, e.g. vegetable stearin, magnesium stearate 
or stearic acid are the most frequently used lubricants in tablets or hard gelatin capsules. 
 
F.  Antiadherents: 
Antiadherents are used to reduce the adhesion between the powder (granules) and the punch 
faces and thus prevent sticking to tablet punches. 
Eg: Talc, starch, silica and magnesium stearate.  
 
 
G.  Colors: 
Colors are added to improve the appearance of a formulation. Color consistency is important 
as it allows easy identification of a medication.  
Eg:  Sunset yellow, fast green, brilliant blue, indigo, carmine, erythrosine and eosin. 
 
H. Flavors: 
Flavors can be used to mask unpleasant taste of active ingredients and to improve the 
likelihood that the patient will complete a course of medication. Flavors maybe natural (e.g. 
fruit extract) or artificial. A bitter product may use mint, cherry or anise, a salty product may 
use peach, apricot or liquorice, a sour product may use raspberry or liquorice and excessively 
sweet product may use vanilla as flavor. 
 
I. Preservatives: 
Preservatives are chemical substance used to improve the shelf life of drugs by decreasing or 
lowering the oxidation of active excipients and by reducing microbial production. Some 
typical preservatives used in pharmaceutical formulations are; 
Eg:  Methyl, propyl, benzyl, butyl p- hydroxy benzoate. 
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J. Sweeteners: 
Sweeteners are added to make the ingredients more palatable, especially in chewable tablets 
such as antacid tablet or liquids like cough syrup.  Sugar can be used to disguise unpleasant 
tastes or smells. 
Eg: Aspartame, sucralose, glycerin, mannitol, sorbitol, acesulfame potasium, saccharin 
sodium etc. 
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1.4 STEPS INVOLVED IN TABLET FORMULATION11 
 Dispensing: Each ingredient in the tablet formula is weighed and accurately 
dispensed as per dose. This is one of the critical steps in any type of formulation 
process and should be done under technical supervision. 
 Sizing: Formulation ingredients must be in finely divided form, otherwise, size 
reduction should be carried out for better flow property and easy mixing. 
 Powder blending: Powders are mixed using a suitable blender to obtain a uniform 
and homogeneous powder mix. The drug substance and excipients are mixed in 
geometric dilution. 
 Granulation: Here small powder particles are gathered together into layers and 
permanent aggregates to render them into free flowing states. 
 Drying and dry screening: Screened wet granules need to be dried for a particular 
time period in tray drier or fluid bed drier at controlled temperature not exceeding 
55°C. Dried granules are screened through the appropriate mesh screen. 
 Tablet compression: This step involves the compression of granules into a flat or 
convex, round, oblong or unique shaped, scored or unscored tablet; engraved with an 
identifying symbol and/ or code number. 
 Coating: Tablets and granules are coated if there is need to mask the unpleasant 
taste/odour of some drug substance or to increase the aesthetic appeal of uncoated 
tablets as well as to modify the release or control the release of drug substance from 
tablets. This is achieved by enclosing or covering the core tablet or granules with 
coating solutions. 
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1.5 TECHNIQUES METHODS USED IN TABLET FORMULATION:  
   Tablets are commonly manufactured by 
 Wet granulation method 
 Dry granulation method  
 Direct compression method. 
One important requirement during tableting is that the drug mixture should flow freely from 
the hopper of the tableting machine into the dies to enable high speed compression the 
powder mix into tablets. 
1.5.1 Manufacture of tablets by wet granulation method  
Wet granulation is a widely used method for the production of compressed tablets. It is 
essentially a process of size enlargement involving several steps and the use of an adhesive 
substance known as binder. The granules produced using this method has a greater 
probability of meeting all the physical requirements for tablet formation. 
 
1.5.2 Manufacture of tablets by dry granulation method 
The formation of granules by compacting powder mixtures into large pieces or compacts 
which are subsequently broken down or sized into granules (often referred to as dry 
granulation, double compression or pre-compression) is a possible granulation method which, 
however, is not widely used in the manufacture of tablets. This method is used when tablet 
excipients have sufficient inherent binding properties. The procedure can also be used as a 
means to avoid exposure of drug substances to elevated temperatures (during drying) or 
moisture. 
  
1.5.3 Manufacture of tablets by direct compression method 
As its name implies, direct compression involves direct compression of powdered materials 
into tablets without modifying the physical nature of the materials itself. The technology 
involved in this method assumes great importance in the tablet formulations, because it is 
often the cheapest means in the production of tablets.  
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Direct compression method avoids many of the problems associated with wet and dry 
granulations. Its successful application in tablet formulation rests on two fundamental issues: 
 The availability of suitable excipients. 
 The availability of suitable machinery. 
1.5.4 Tablet compression12: 
After the preparation of granules (in case of wet granulation) or sized slugs (in case of dry 
granulation) or mixing of ingredients (in case of direct compression), they are compressed to 
get final product. The compression is done either by single punch machine (stamping press) 
or by multi station machine (rotary press). The different stages of compression process 
include filling, metering, compression.  
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1.6 EVALUATION OF TABLETS13: 
The tablet is the most popular dosage form as they were easy in preparation compared to 
any other type of dosage forms. But the major drawback exists in its manufacturing. If 
any minor problem occurs during their manufacturing, then the whole batch of the unit 
should be discarded. It is necessary to avoid any sort of errors during its manufacturing 
and as a result evaluation of tablets is very important before dispatching of a batch. 
Evaluation of tablets can be carried out by official and unofficial tests.  
    a) Unofficial tests  
 Appearance  
  Size and Shape  
  Organoleptic properties  
  Uniformity of thickness  
  Hardness 
 Friability 
b) Official tests 
 Weight variation test 
 Content uniformity 
 Disintegration test 
 Dissolution test 
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                         1.7 CHEWABLE TABLETS 
Chewable tablets are an immediate release (IR) oral dosage form intended to be chewed and 
then swallowed by the patient rather than swallowed whole. They should be designed to have 
a pleasant taste and be easily chewed and swallowed.14 Chewable tablets should be safe and 
easy to use in a diverse patient population, pediatric, adult or elderly patient, who is unable or 
unwilling to swallow intact tablets due to the size of the tablet or difficulty with swallowing. 
The availability of safe, easy-to-use dosage forms is important in clinical practice. Chewable 
tablets are available for many over-the-counter (OTC) and prescription drug products.15 The 
United States Pharmacopeia (USP) recognizes and differentiates between two types of 
chewable tablets: (1) those that may be chewed for ease of administration and (2) those that 
must be chewed or crushed before swallowing to avoid choking and/or to ensure the release 
of the active ingredient. The concepts in this guidance are applicable to both types of 
chewable tablets.16 
Advantages of Chewable Tablets:17 
 Patient convenience. 
  Substitute for liquid dosage forms.  
 Improved patient acceptance. 
 Better bioavailability. 
 Provides proper unit dosage form of medication. 
 Disadvantages of Chewable Tablets: 
 Bad tasting drugs should not be suitable. 
 Drugs having high dosage levels should be difficult to formulate. 
 These tablets may contain sorbitol which can cause diarrhoea and flatulence. 
 Prolonged chewing of these tablets results in pain in facial muscles. 
 They require proper packaging for safety and stability of drug. 
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The several aspects to be considered in formulation of chewable tablets are shown in fig.1 
   
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Fig 1: Various Aspects to be Considered in Formulation of Chewable Tablets 
 
  
        TYPICAL PRODUCTS 
    Vitamins, Antacids, Analgesics, 
               Cold Remedies 
FORMULATION FACTOR 
Amount of active substances as 
a percent of total tablet weight 
Flow 
Lubrication 
Disintegration 
Compressibility 
Compactability- Stability 
Organoleptic considerations 
 
     DESIRED PRODUCT          
 ATTRIBUTES 
a. Good taste and mouthfeel, 
acceptable bioavailability and 
bioactivity. 
b. Acceptable stability and 
quality economical formula 
and process. 
EVALUATION 
a. Taste panels, blood 
levels (for absorbed 
drugs) in vitro vs in vivo 
correlation.  
b. Stability 
(chemical,physical, 
organoleptic) 
c. Quality control and 
assurance. 
                               FORMULATION TECHNIQUES AND APPROACHES 
1. Microencapsulation      4. Spray congealing and coating             7. Artificial sweeteners 
2. Solid dispersion            5. Granulation and coating                            8. Flavoring 
3. Ion exchange       6. Inclusion complexes, molecular complexes   
       Flow chart of Various Aspects to be Considered in Connection with     
       Chewable Tablets 
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1.7.1 GENERAL FORMULATION FACTORS TO BE CONSIDERED IN 
THE FORMULATION OF CHEWABLE TABLETS 18 
Various factors are involved in the formulation of chewable tablets. The major formulation 
factors are flow property, lubrication, disintegration, organoleptic properties, compressibility, 
compatibility and stability, which are common to regular (swallowed) and chewable tablets; 
however, organoleptic properties of the active drug substances are primary concern here. A 
formulator may use one or more approaches to arrive at a combination of formula and 
process that results in product with good organoleptic properties. Such a substance must have 
acceptable flow, compressibility and stability characteristics.  
 A. Taste and Flavor 
 Physiologically, taste is a sensory response resulting from a chemical stimulation of the taste 
buds on the tongue. There are four basic type of taste; salty, sour, sweet and bitter. Salty or 
sour tastes are derived from substances capable of ionizing in the solution. Many organic 
medicinal compounds stimulate a bitter response even though they may not be capable of 
ionizing in an aqueous medium. Most saccharides, disaccharides, some aldehydes and few 
alcohols give a sweet taste. Substance incapable of producing a sensory stimulation of the 
buds is known as tasteless. The term flavor generally refers to a specific combined sensation 
of taste and smell. For example, sugar has a sweet taste, but no flavor, whereas honey has a 
sweet taste and a characteristic smell. 
B. Aroma19 
Pleasant smells are generally referred to as aromas. For example, a well formulated, orange-
flavored chewable tablet should have a characteristic sweet and sour taste and aroma of fresh 
orange.  
C.  Mouth-Feel  
This term is related to the type of sensation or touch that a tablet produce in the mouth upon 
chewing. As such, it has nothing to do with chemical stimulation of olfactory nerves or taste 
buds. However, for a formulation to be successful, the overall effect in the mouth is 
important. In general, gritty (e.g., calcium carbonates) or gummy texture is undesirable, 
whereas soothing and cooling sensation (e.g., mannitol) with smooth texture is preferred.  
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 D. After Effects 20 
The most common after effect of many compounds is after taste. For example, some irons 
leave a “rusty” after taste; saccharin in high amounts tends to leave a bitter after taste. 
Another common after effect is a numbing sensation of a portion or the whole surface of the 
tongue and mouth. Bitter anti-histamines like Pyribenzamine hydrochloride and 
Promethazine hydrochloride are typical of this class drugs.  
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1.7.2 ASSESSMENT OF PHYSICO-CHEMICAL PROPERTIES OF 
ACTIVE DRUG IN THE FORMULATION OF CHEWABLE TABLETS21  
Wherever feasible and practical, the first step in the formulation of chewable tablet is to 
obtain a complete profile of the active drug. This usually leads to the most efficient 
formulation of a stable and quality product as the drug usually dictates the choice of fillers, 
carriers, sweeteners, flavor compounds and other product modifiers. The drug profile ideally 
should contain information on the following: 
A.  Physical Properties   
 Color   
 Odor     
 Taste, after-taste and mouth-feel   
 Physical form: Crystal, powder, amorphous solid, oily liquid, etc. 
 Melting temperature 
 Polymorphism 
 Moisture content,  aqueous solubility 
 Active drug stability 
B. Chemical Properties 
 Chemical structure and chemical class 
 Major reactions 
 Major incompatible compounds  
 Drug dose   
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1.7.3 “TASTE”- A NECESSARY REQUIREMENT FOR CHEWABLE 
TABLETS 22 
A. Physiology of Taste 
Generally human tongue contains 50-100 numbers of taste buds. It has onion shaped 
structure. Chemical from foods or orally ingested medicaments are dissolved by saliva via 
taste pores. They either interact with surface proteins known as taste receptors or ion-
channels. Taste sensation can be expressed as a feeling by an individual when something is 
given into mouth in order to ascertain the whole component. There are generally four 
fundamental types of taste. 
     Sweet and salty, mainly at the tip of tongue   
     Sour, at the side of tongue   
     Bitter, at the back of the tongue  
 
B. Taste Masking 
Taste masking is defined as a reduction of undesirable taste that would otherwise exist. Taste 
masking can be achieved using taste masking agents, specific flavors and sweeteners. 
Sweeteners are essential to complete the experience and produce a pleasant taste of the 
product. This is one of the major limiting factors in the formulation of oral dosage forms 
having unpleasant taste. Flavor masking and processing approaches are two primary methods 
to overcome this problem. Flavor masking generally include addition of flavor, sweetener, 
lipid and acids.  
 
C. Techniques for Taste Masking  
Taste-masking techniques often go hand in hand with the formulation technology. In short, 
they need to be mutually compatible. For example, coated particles obtained after fluid-bed 
coating should be able to withstand the tablet compression process used for the final dosage 
form (tablet) manufacturing. The commonly used industrial techniques/methods of taste-
masking include, 
 Organoleptic methods 
 Polymer coating 
 Hot-melt extrusion  
 Microencapsulation  
 Complexation 
 Spray-drying 
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1.7.4 GENERAL EXCIPIENTS USED IN THE FORMULATION OF 
CHEWABLE TABLETS23 
 The acceptability in the formulation of chewable tablets will be primarily determined by 
taste and to a lesser degree, appearance. Therefore, appropriate selection and use of 
components that impact on these properties are of extreme importance. Major excipients, 
such as fillers or direct compaction vehicle have the major role in the outcome of these 
concerns. Many of the sweeteners commonly used in the tablet formulation are especially 
applicable for use in chewable tablets due to their ability to provide the necessary properties 
of sweetness and chewability. In general all these excipients fall under the sugar category, 
although a combination of bland excipients with artificial sweeteners may provide a 
satisfactory alternative. Some common chewable tablet sweeteners are brown sugar, 
compressible sugar, honey, dextrose, lactose, mannitol, sorbitol, etc. 
 
A. Sweeteners  
 
 Dextrose  
Dextrose is the sugar obtained through the complete hydrolysis of starch. Its sweetness level 
is approximately 70% that of sucrose and is available in both anhydrous (but hygroscopic in 
nature) and monohydrated form. 
 Lactose  
Lactose is the monosaccharide produced from whey, a byproduct of the processing of cheese. 
Although generally acknowledged as the most widely used pharmaceutical excipient in the 
world, its applicability to chewable tablets is less, due to its extremely low sweetness level. 
This deficiency requires the addition of an artificial sweetener of sufficient potency to 
overcome lactose’s blandness. 
  Mannitol  
Mannitol is a white, crystalline polyol approximately 50% as sweet as sucrose. It is freely 
soluble in water and, when chewed or dissolved in the mouth, imparts a mild cooling 
sensation due to its negative heat of solution. 
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B. Flavors 
Taste is almost certainly the most important parameter in the evaluation of chewable tablets. 
Taste is a combination of the perceptions of mouth feel, sweetness and flavor. Flavoring 
agents are available in a variety of physical forms from a large number of suppliers 
specializing in these materials. Virtually all offer technical support services, which will be 
addressed in the section on flavor formulation.  
Various groups of flavors for general baseline taste types are presented in table 1.  
 
     Table: 1 Flavor Groups for General Baseline Taste Types 
Sweet Grape, berries, honey, vanilla 
Sour (acidic)  Citrus, liquorice, strawberry, cherry 
Salty  Buttery, spice, mixed citrus, mixed fruit 
Bitter  Liquorice, wine, mint, nut, fennel, grapefruit 
 
    C.  Colorants  
 To increase aesthetic appeal 
 To mask non uniform colour of raw materials  
 Aid in product identification and differentiation 
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1.7.5 GENERAL METHODS OF MANUFACTURING CHEWABLE 
TABLETS24  
 
The chewable tablets were prepared by using the following methods:  
1. Non aqueous Granulation/Dry Granulation  
2. Aqueous Granulation/Wet Granulation  
3. Direct Compression  
 
Granulation  
Granulation is the process in which primary powder particles are made to adhere to form 
larger, multi-particles entities called granules. Pharmaceutically granules have size range 
between 0.2 to 4.0 mm. Granulation is used to improve flow and compressibility of powders 
and to prevent segregation of the blend components. Granulation is mainly done by using two 
techniques.  
 
Dry Granulation  
It is the novel method for semi-automatic production of granules. The method is applicable to 
any solid dosage pharmaceutical products. Dry granulation method replaces existing solid 
dosage form development and manufacturing technologies offering more rapid development 
and better quality. In this process, the powder mixture is compressed without the use of heat 
and solvent. Two methods are used for dry granulation. The more widely used is slugging 
where the powder is recompressed and the resulting tablets are milled to yield the granules.  
 
Wet Granulation  
Wet granulation is the most commonly used granulation method. This process involves wet 
massing of powder blend with a granulating liquid, wet sizing and drying. The granulating 
liquid contains a solvent which must be volatile so that it can be removed by drying and must 
be non-toxic in nature. Typical liquid include water, ethanol and Isopropyl alcohol. In the 
traditional wet granulation method the wet mass is forced through a sieve to produce wet 
granules which are subsequently dried.  
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Direct Compression25  
Direct compression is the most popular choice because it provides the shortest, most effective 
and least complex way to produce tablets. This method is mainly used when a group of 
ingredients can be blended. This is more suitable for moisture and heat sensitive API. 
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1.7.6 EVALUATION PARAMETERS FOR CHEWABLE TABLETS26 
 
A. Physical Evaluation  
It involves the following:  
1. Tablet physical appearance  
2. Hardness  
3. Friability  
4. Disintegration  
5. Dissolution 
 
B. Chemical Evaluation  
It involves the following:  
1. Assay of drug content  
2. Dosage uniformity  
3. In vitro and In vivo evaluation 
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1.7.7 STABILITY TEST FOR CHEWABLE TABLETS27  
Stability testing of dosage forms or drug products is carried out to evaluate time dependent 
changes. Accelerated stability testing is used to predict quickly the potential changes that may 
occur in a product. There are three areas of major concern in the stability testing of chewable 
tablets such as organoleptic, chemical, physical parameter evaluation. The data obtained from 
chemical evaluation of the tablets at elevated temperature and humidity, stress conditions are 
most useful. 
 
Other tests in the stability program would include:  
 Active drug content determination. 
 Changes in physical characterization of the tablets.  
 Changes in the tablet hardness, friability, dissolution rate and extent of dissolution. 
 Moisture content of the tablets. 
 Stability of the coating systems. 
 Stability of the colorants. 
 
 
. 
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CHAPTER-2 
REVIEW OF LITERATURE 
 
Shruthi.K et al., (2013)28 formulated and evaluated Montelukast sodium chewable tablets  
prepared by wet granulation method using different concentrations of xanthan gum, karaya 
gum, modified karaya gum as diluents and sodium starch glycolate (SSG) as disintegrant. 
The tablets were evaluated for various parameters such as general appearance, diameter, 
thickness, hardness, weight variation, wetting time, friability, disintegration time, drug 
content estimation and in vitro dissolution studies. The results were found to be satisfactory 
and within specifications. Formulation F12 containing modified karaya gum 30% and SSG 
4% was selected as optimized formulation, as it showed complete drug release in 90 minutes. 
Comparison studies were performed for optimized and marketed formulations and difference 
(F12) and similarity factors (f2) values were found to be 3.82 and 75.12% respectively. The 
optimized formulation (F12) was subjected to stability studies for three months as per ICH 
guidelines and showed good physical stability with significant changes in physical 
appearance and quality control tests. Hence it can be concluded formulation F12 containing 
modified karaya gum 30% and SSG 4% fulfilled all the criteria for chewable tablets. 
Errolla Mahesh et al., (2009)29 formulated Montelukast sodium chewable tablets by  using 
novel co-processed superdisintegrants consisting of crospovidone and sodium starch 
glycolate in the different ratios (1:1, 1:2 & 1:3) and vice versa. Montelukast sodium is a drug 
of choice in treatment of asthma and allergic rhinitis. Drug compatibility with excipients was 
checked by FT-IR studies. The flow properties of the powder blends were found to be within 
prescribed limits and indicated good flow property. All the formulations were subjected to 
post compression parameters. Hardness and friability test indicated that tablets had a good 
mechanical strength and resistance. Drug content was found to be in the range of 93.51 to 
98.79 %. The wetting time of all formulations were found to be in the range of 20 to 55 sec. 
Among all the designed formulations, formulation F9 was found to be promising and showed 
an in vitro disintegration time of 25 sec, which facilitates faster disintegration in the mouth. 
When compared to marketed product, the formulation F9 containing co-processed 
superdisintegrants (1:3 mixture of sodium starch glycolate and crospovidone) emerged as the 
overall best formulation based on drug release characteristics. Short-term stability studies on 
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promising formulation F9 indicated that there were no significant changes in hardness, drug 
content and   in vitro drug release.  
Kanakadurga Devi. N et al., (2012)30  formulated and evaluated fast mouth dissolving 
chewable tablets of Montelukast sodium by direct compression method with three 
superdisintegrants (i.e) polyplasdone XL10, Ac-Di-Sol and Primojel. The pure drug and 
formulation blend was examined for angle of repose, bulk density, tapped density, 
compressibility index and Hausner’s ratio. The tablets were evaluated for hardness, tensile 
strength, drug content, friability and were found satisfactory. Disintegration time in the oral 
cavity was also tested and was found to be around 9 sec. Based on dissolution rate the 
disintegrants can be rated as polyplasdone XL10 > Ac-Di-Sol > Primojel. Hence 
polyplasdone XL10 was recommended as suitable disintegrant for the preparation of direct 
compression melt-in-mouth tablets of Montelukast sodium. All the dissolution parameters 
were calculated and compared with market tablet. An increase in the dissolution rate was 
observed with M8 formulation when compared to market tablet. Hence it was concluded that 
the rapidly disintegrating tablets of Montelukast sodium with proper hardness, rapid 
disintegration in the oral cavity with enhanced dissolution rate can be made using 
polyplasdone XL10. 
Alaa Eldin A. Kassem et al., (2017)31 prepared fast dissolving sublingual films of 
Montelukast sodium (MS) using solvent casting technique. Tween 80 was used as 
solubilizing agent, Propylene glycol as plasticizer and mannitol as sweetener. The 
compatibility between the drug and film formers was investigated using Fourier Transform 
Infrared spectroscopy and Differential Scanning Colorimetry studies. The developed 
formulations were characterized for physico-mechanical properties and pharmacokinetic 
parameters. Simple, validated HPLC analysis method was used to compare the bioavailability 
of the chosen prepared sublingual film containing 5% w/w hydroxyl propyl methylcellulose 
E15 and the commercial product (Kokast®) after their sublingual administration to albino 
rabbits. The results showed that all physico-mechcanical properties and pharmacokinetic 
parameters were within the acceptable limits. Hence it can be concluded  that formulation F5 
(5 %w/w HPMC) is very much promising as sublingual film of MS with excellent physical 
appearance, suitable weight and thickness values, least disintegration time, highest 
dissolution rate, highest Cmax and AUC and best relative bioavailability. 
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Jahufar Sathik et al., (2011)32 developed and evaluated bilayer tablet of Montelukast 
sodium and Levocitrazine HCl using superdisintegrants such as croscarmellose sodium and 
starch granules. IR spectrum revealed that there is no disturbance in the principle peaks of 
pure drugs of Montelukast sodium and Levocetrizine HCl. The angle of repose was ranged 
from 25.0˚±1.40 to 31.4˚±0.97 for Montelukast sodium and 25.2˚±1.40 to 29.5˚± 0.68 for 
Levocetrizine HCl. The compressibility index was found in the range of 11.6 to 22.2 for 
Montelukast sodium and 14.1 to 27.8 for Levocetrizine HCl. Hausner’s ratio was found to be 
1.143 to 1.287 for Montelukast sodium and 1.41 to 1.46 for Levocetrizine HCl. The results of 
the angle of repose indicates good flow property of the granules and the values of 
compressibility index further showed support for the flow property. The prepared tablets 
were evaluated for hardness, friability, weight variation, drug content uniformity and in vitro 
release studies. The results were found to be within the limits. The stability studies were 
carried out for the optimized formulation for three months and it show acceptable results. 
Among the various formulations prepared, Formulation F8 with croscarmellose sodium 
(20%) shows minimum disintegration time and improved dissolution properties and emerged 
as best formulation. This is because of the dual action of wicking and swelling property of 
disintegrants. Hence, it is finally concluded that, the bilayer immediate release tablets of 
Montelukast sodium and Levocetrizine HCl can be used for alternative dosage form in the 
effective treatment of patients suffering from allergic rhinitis and bronchial asthma. 
Hosseinali Tabandeh et al., (2013)33 developed Ferrous fumarate chewable tablets by 
simplex experimental method. The mathematical experimental design was used as the 
formulation approach. Different series of formulations based on single filler (Lactose granule, 
mannitol granule and three Avicels) were prepared and evaluated. The total filler percentage 
in formulation was kept constant at 40% and simplex lattice mixture design was used with 
percentages of each of the three selected fillers as factors and hardness, friability and taste of 
the resulted tablets as responses. The statistical analysis and optimization were performed by 
Design Expert software using responses in suggested experimental runs. Two-way analysis of 
variance and Scheffe Post-Hoc test showed that both the type and amount of fillers were 
effective on hardness. Avicel PH 301 was selected as the filler for imparting higher hardness 
and lactose and mannitol granules for imparting good taste and mouth feel to tablets. The 
mathematical optimization suggested the acceptable formulations of Ferrous fumarate 
chewable tablets. The mathematical experimental design is suggested as a promising efficient 
method for optimization of pharmaceutical formulation projects with multiple goals. 
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M. Rajesh et al., (2012)34 developed Albendazole chewable tablets by wet granulation 
method using two superdisintegrants such as croscarmellose sodium and sodium starch 
glycolate. A total of eight formulations were prepared and the granules were evaluated for 
precompression parameters such as angle of repose, bulk density, tapped density, 
compressibility index and Hausner’s ratio. The formulated tablets were evaluated for 
diameter, thickness, hardness, weight variation, friability, disintegration, drug content and 
drug release study. The results showed that all the physical parameters were within the 
acceptable limits. IR spectral studies revealed that there was no interaction between the drug 
and excipients. The in vitro release study of formulation F8 showed 81.03% drug release at 
the end of 30 min. The stability studies for the formulation F8 showed no significant change 
in disintegration time, drug content and percentage drug release after stored at 
40o±2oC/75±5%RH for a period of 30 days. Hence it can be concluded that formulation F8 
showed better characteristics of chewable tablets. 
 
V. Anil kumar et al., (2016)35 formulated and evaluated chewable tablets of Almotriptan by 
direct compression method by using various superdisintegrants like (Crospovidone, 
croscarmellose sodium, sodium starch glycolate). All the tablets were subjected to weight 
variation, drug content uniformity, lock length, dissolution, drug excipients interaction and 
short-term stability studies. There was no difference in the position of the absorption bands, 
hence providing evidence for the absence of any chemical incompatibility between pure drug 
with the excipients. The bulk density and tapped density for all formulation (F1 –F9) varied 
from 0.423 - 0.485 gm/cm3 and 0.501 - 0.593 gm/cm3 respectively. The results of carr’s 
consolidate index or % compressibility index and hausner’s ratio for the entire formulation 
(F1 – F9) blend range from 15.5- 19.1% and 1.10-1.28 respectively, shows fair flow 
properties. All the tablets showed similar color, odour, taste and physical appearance. The 
hardness values ranged from 3.0-3.5 kg/cm2 for formulations (F1-F9). The entire tablets 
passed the weight variation test, as the average % weight variation was within the 
Pharmacopeial limit (±7.5%). The concentration of the drug in all the formulations with 
different polymers was found to be 97.35 – 99.58%. It was within the IP limit. It can be 
concluded that formulated immediate release tablets of Almotriptan exhibited good physical 
parameters. The overall results indicated that formulation F6 with croscarmellose (7.5%) had 
a higher edge with good palatability compared to other formulations. 
 
CHAPTER- 2                                                                             REVIEW OF LITERATURE 
 
S.B.C.P  DEPARTMENT OF PHARMACEUTICS  Page 31 
 
Fatima, et al., (2016)36 developed and evaluated chewable tablets of Clarithromycin using 
ion exchange resins. The present investigation aims at taste masking of the bitter 
Clarithromycin using ion exchange resins, which forms complexes, inhibiting its release in 
saliva. The drug-resin complex loading process was optimized for the content of resin, 
activation, swelling time, stirring time, influence of pH and temperature for maximum drug 
loading and was subjected to differential scanning colorimetry to confirm the complex 
formation. These complexes were used to prepare chewable tablets and to evaluate the taste. 
Acid-activated resins comprising of Indion 204, Indion 234 and Tulsion 335 with drug: resin 
ratio of 1:2, stirred in solution of pH 7-8 at 70°C for 6 h had a maximum drug loading and 
masked the bitter taste of Clarithromycin. The drug-resin complex was formulated into 
chewable tablet formulations (F1-F9) and evaluated. Various pre and post-compression 
parameters were found to be within permissible limits. Formulations F3, F6 and F9 
containing 1:2 ratios of drug-resin complex of Indion 204, Indion 234 and Tulsion 335 
revealed maximum taste masking. This was further confirmed by treatment of taste 
evaluation scores of the volunteers by ANOVA, Dunnets multiple comparison test and 
Tukey’s multiple comparison test. All the three optimized formulations had a significant 
difference of P<0.001 when compared to control F10. Formulation F6 was emerged as a best 
formulation. Hence it was concluded that Ion exchange complexation could efficiently mask 
the bitter taste of Clarithromycin and achieve palatable taste suitable for pediatric use. 
 
Sumalatha et al., (2015)37 formulated and evaluated polyherbal chewable tablets for 
reducing nicotine dependence. Plants have always been an experimental source of drugs and 
many of the currently available drugs have been derived directly or indirectly from them. 
Following all data and knowledge, chewable tablets for smoking cessation was prepared 
using Ginger (Zingiber officinale), Tulsi (Ocimum sanctum), Almond (Prunus amygdalis), 
Fennel (Foeniculum vulgare), Cinnamon (Cinnamomum zeylanicum), Clove (Eugenia 
caryophyllus), Cardamom (Elettaria cardamomum) with acacia gum 5% w/v) as a binding 
agent, sorbitol as sweetening agent. Poly herbal chewable tablets were prepared by wet 
granulation technique by using acacia gum 5% w/v) as a binding agent. Tablets were 
evaluated for weight variation test, friability, hardness; time required for complete chewing 
and all the values are found within acceptable limits. It can be concluded that the selected 
formulation of poly herbal chewable tablets has acceptable physicochemical features and may 
be considered as herbal medication for reducing nicotine dependence.  
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Mahalaxmi Rathnanand et al., (2013)38 formulated and evaluated Metformin chewable 
tablets using stevia by three methods viz non aqueous granulation, aqueous granulation and 
direct compression. Various evaluation parameters like thickness, hardness, friability, weight 
variation and drug content of the formulations were tested and found to be satisfactory. All 
the formulations showed similar thickness. Tablets from different formulations showed 
hardness in the range of 4 - 4.3 Kg/cm2. All formulations passed the USP requirement in 
terms of weight variation and drug uniformity. All the formulations showed disintegration 
time below 15 min. Release profile of the optimized formulation prepared by wet granulation 
technique showed satisfactory release within 30 min. The variation in the dissolution rate of 
Metformin chewable tablets made by different techniques were in the following order, direct 
compression< non-aqueous granulation< aqueous granulation. Hence it can be concluded that 
chewable tablets of Metformin HCl prepared by wet granulation method had faster 
dissolution rate within 30 min compared to remaining batches. 
 
Bharat et al., (2012)39 prepared Albendazole chewable tablets by three methods viz. non 
aqueous granulation, aqueous granulation and direct compression. Tablets prepared by these 
three methods were evaluated for different parameters such as Average weight, hardness, 
carr’s index, tapped density, friability, disintegration, water content, in vitro dissolution etc. 
All the parameters were found within the specifications. All the tablets showed good 
hardness. Batch ‘AG’ had minimum hardness (5.1±0.10 kg/cm2) while ‘DC’ had maximum 
hardness       (5.5±0.09 kg/cm2). The friability was less than 0.2% for all the formulations and 
was satisfactory. Assay value of all prepared batches of Albendazole tablets were within the 
range of 90% to 110% of stated amount of Albendazole. From the data obtained it was found 
that 88.8% of drug was released for the trial ‘DC’ at 30 min while other trials ‘NG’ and ‘AG’ 
had shown 81% & 80.5% drug release at 30 min respectively. The variation in the dissolution 
rate of Albendazole tablets was in the following order AG<NG<DC.  The study revealed that 
the tablets prepared by ‘Direct compression’ had faster dissolution rate while compared to 
remaining batches and marketed product.  
 
Swati Jagdale et al., (2010)40 formulated and evaluated chewable tablets of Levamisole 
which is used in the treatment of worm infestations. The chewable tablets of Levamisole 
were prepared by using lactose or mannitol along with sodium starch glycolate as 
superdisintegrant especially for paediatric use. Sodium saccharin and vanilla were used as 
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sweetening agent and flavouring agent respectively. It was observed that the formulation 
containing lactose shows less disintegration time than formulation containing mannitol. The 
overall results revealed that Levamisole chewables tablet containing lactose and sodium 
starch glycolate showed minimum disintegration time, sufficient hardness, pleasant taste, 
better  dissolution rate and was considered as best formulation. 
 
Kathiresan K et.al., (2010)41 formulated and evaluated 5 batches of Loratadine chewable 
tablets. Loratadine, which is histamine H1 receptor antagonist was used in the treatment of 
allergic rhinitis and urticaria. Results showed that thickness, weight variation, friability, 
hardness and content uniformity of all formulations were within the acceptance limits. But in 
the in vitro dissolution study, formulations 1, 2 and 5 demonstrated better cumulative drug 
release than formulations 3 and 4. However, cumulative drug release of formulation 5 was 
comparable with innovator than formulations 1 and 2. Hence the study concludes that 
Loratadine chewable tablets formulated using Avicel CE 15 and starch paste showed better 
characteristics of chewable tablets. 
 
M. Rajesh et al., (2018)42 formulated and evaluated sugar free Sucralfate chewable tablets by 
wet granulation method using croscarmellose sodium and sodium starch glycolate as 
superdisintegrants and neotame as non calorific sweetener. The formulated tablets were 
evaluated for thickness, hardness, weight variation, friability, disintegration test, drug 
content, acid neutralizing capacity and in vitro dissolution studies. The FT-IR spectral studies 
revealed that there was no interaction between the drug and excipients. Formulation    SCT-7 
showed rapid drug release (92.3%) at the end of 25 minutes and good acid neutralizing 
capacity (17.44 mEq) compared to other formulations. Hence it can be concluded that 
formulation SCT-7 containing combination of two superdisintegrants (croscarmellose sodium 
and sodium starch glycolate) was found to be the better one which satisfied all the criteria for 
chewable tablets.  
 
Sabina Akhtar et al., (2017)43 developed chewable multivitamin tablets by direct 
compression method and to ensure that they are easily crushed by chewing.  The excipients 
used in this study are mannitol, sucrose, starch, talc, magnesium stearate and vanilla powder.  
Multivitamins used are ascorbic acid, riboflavin, nicotinamide, thiamine HCl. The powder 
blend was evaluated for various precompression parameters. The formulated tablets were 
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evaluated for post compression parameters. The tablets showed immediate drug release and 
all the parameters were found within the specification. Drug content of ascorbic acid was 
found to be (103.62% - 108.84%), riboflavin (99.88% - 112.02%), nicotinamide (93.44% - 
100.31%) and thiamine HCl (105.94% - 108.5%). The results conclude that the multivitamin 
chewable tablets could be successfully prepared by direct compression method. 
 
A Halder et al., (2013)44 formulated and evaluated chewable tablets of Loperamide by wet 
granulation technique using microcrystalline cellulose and crosscarmellose sodium. The 
prepared tablets showed good physical characteristics, drug content and percentage of drug 
release. Among the 6 formulations, F1 showed better drug release (96%) and drug content 
(98.38%). Further, F1 was selected for the method development and validation purpose. The 
validation data indicates the suitability of the developed chromatographic method which is 
easier and cost effective than the other reported and official methods. 
 
 Sree Giri Prasad et al., (2012)45 formulated Montelukast chewable tablets by both wet 
granulation and direct compression methods using suitable excipients. A total of eight 
formulations were prepared and the granules were evaluated for precompression parameters. 
The formulated tablets were evaluated for post compression parameters. The results showed 
that all the physical parameters were within the acceptable limits. I.R spectral studies 
revealed that there was no interaction between the drug and excipients. The in vitro release 
study of formulation F7 showed 98.85% drug release at the end of 30 min. The stability 
studies for the formulation F7 stored at 400 C / 75% RH and room temperature for three 
months showed no significant changes. Hence it can be concluded that formulation F7 
prepared by direct compression method showed better characteristics of chewable tablet. 
 
Dhruba Sankar et al., (2014)46 developed and evaluated Paracetamol and Metoclopramide 
hydrochloride chewable tablets by wet granulation method to study the effect of different 
proportion of Aerosil, croscarmellose sodium, crospovidone and neem gum. Maize starch 
was used as binding agent. Tartrazine was used as coloring agent. Aspartame and vanilla 
flavor were used as sweetening agent and flavoring agent respectively. Several 
physicochemical parameters like thickness, diameter, hardness, % weight variation, % loss in 
weight, drug content, disintegration time, in vitro dissolution studies, kinetics of drug release 
and stability study for all the formulations were studied and were found within the acceptance 
limits. Formulation F10 containing neem gum (1%) showed best cumulative drug release for 
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Paracetamol (99.55%) and Metoclopramide hydrochloride (98.59%) and emerged as best 
formulation. 
 
D Kumar et al., (2014)47 developed and evaluated Paracetamol and Metoclopramide  
hydrochloride chewable tablets by wet granulation method to study the effect of different 
proportion of Aerosil, croscarmellose sodium, crospovidone and moringa gum. Maize starch 
was used as binding agent. Several physicochemical parameters like thickness, diameter, 
hardness, % weight variation, % loss in weight, drug content, disintegration time,       in vitro 
dissolution studies, kinetics of  drug release and stability studies for all the formulations were 
studied and were found within the acceptance limits.  Formulation F7 containing  moringa  
gum  (1%)  showed  the  best  cumulative drug release for Paracetamol (97.32%) and 
Metoclopramide hydrochloride (96.45%) and emerged as best formulation. 
 
Ashok Kumar et al., (2014)48 formulated Pentoxifylline loaded chewable tablets for the 
treatment of peripheral vascular disease. The chewable tablets were prepared by using wet 
granulation technique. Lactose and mannitol were used as diluents with different 
concentration of sodium starch glycolate (SSG) as superdisintegrant. Prepared granules were 
subjected to precompression studies like angle of repose and compressibility index. The 
compressed formulations were then evaluated for appearance, thickness, weight variation, 
hardness, friability, drug content uniformity, wetting time, disintegration time and in vitro 
drug release profile. The in vitro drug release profile was carried out in phosphate buffer 
(PBS pH 6.8) at 37±0.1ºC using USP paddle Type II. The results of all evaluation parameters 
were found within acceptable limits. The formulation containing 4.0% w/w of sodium starch 
glycolate showed minimum disintegration time and showed 97.82 % drug release in 30 
minutes than other formulations and emerged as the overall best formulation. 
Jayapal Reddy et al., (2011)49 formulated and evaluated polyherbal chewable tablets for 
cough remedy. Plants have always been an exemplary source of drugs and many of the 
currently available drugs have been derived directly or indirectly from them. Chewable 
tablets for cough remedy was prepared using Liquorice (Glycyrrhiza glabra), Ginger 
(Zingiber officinale), Black pepper, Tulsi (Ocimum sanctum), Pudina (Mentha piperita), 
Fennel (Foeniculum vulgare), Cinnamon (Cinnamomum zeylanicum), Clove (Eugenia 
caryophyllus) Ajowan and Amla with 10% starch as a binding agent. Chewable herbal tablets 
were prepared by wet granulation technique. Prepared tablets were evaluated for weight 
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variation test, friability, hardness; time required for complete chewing and was found to be 
within the acceptable limits. DSC and FT-IR spectral studies showed that there was no 
interaction between the drug and excipients. It can be concluded that the selected formulation 
of chewable herbal tablets has acceptable physicochemical features and may be considered as 
herbal medication for cough remedy.  
Hemali Soni and A Patel (2016)50 prepared raft forming chewable tablets of Ranitidine 
hydrochloride by using raft forming agents like pectin, sodium bicarbonate, calcium 
carbonate for effective treatment of Gastro Esophageal Reflux Disease. The tablets were 
evaluated for various physicochemical parameters and in vitro drug release study. Tablets 
showed satisfactory results when evaluated for hardness, friability, weight variation, drug 
content, raft strength and acid neutralizing capacity. Out of all factorial batches (i.e.) PB1 to 
PB10, PB8 has shown promising results of raft strength as it is sufficient for the prevention of 
the reflux and fulfilled all the criteria for chewable tablets. 
Mitul Patel et al., (2014)51 formulated raft forming chewable tablets of Pantoprazole sodium 
along with raft forming agents sodium alginate and pectin and antacid (NaHCO3). The tablets 
were prepared by wet granulation method and evaluated for raft strength, acid neutralization 
capacity and in vitro drug release. The tablets containing appropriate amount of sodium 
alginate with pectin showed highest raft strength. Raft strength was affected by amount of 
sodium alginate, pectin and sodium bicarbonate. A 3 2 full factorial design was used in 
present study of optimization. Acid neutralization capacity and in vitro drug release of all 
batches was found to be satisfactory. F8 batch was optimized based on maximum raft 
strength and good acid neutralization capacity and in vitro drug release. Stability study of 
optimized formulation showed that the tablets were stable at accelerated condition and 
fulfilled all the criteria for chewable tablets. 
 
 Ravi Subhashini et al., (2013)52 developed fast dissolving chewable tablets of Domperidone 
using Plantago ovata mucilage as a natural superdisintegrant. The tablets were prepared by 
direct compression method using microcrystalline cellulose as a directly compressible 
vehicle. Tablets each containing 10 mg of Domperidone were prepared by employing super-
disintegrant at five different concentrations of 2.5%, 5%, 7.5%, 10% and 12.5%. Tablets were 
evaluated for their physicochemical properties such as weight variation, thickness, hardness, 
disintegrating time, wetting time and in vitro drug release study. Values of angle of repose 
were found in the range of 18.26o to 19.93o showing that the powder blend was free flowing 
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and can be used for direct compression. The value of carr’s index was in between 10-15% 
indicating that all the batches of powder blends were having good compressibility. Thickness 
was observed between 4.1- 4.5 mm, hardness of the tablet was in the range of 3.0-3.9 kg/cm2 
and weight loss in the friability was less than 1% in all the cases. Among all the formulations 
of Domperidone F5 (12.5%) was found to have less disintegration time, wetting time, in vitro 
dispersion time (i.e.) 28 sec, 22 sec and 32 sec respectively and 100% drug release at 12 min.   
Hence it can be concluded that F5 (12.5%) was found to be better formulation than F1, F2, F3 
and F4. 
 
Fiza F et al., (2014)53 developed an effective formulation of Mebendazole chewable tablets 
by three methods viz non aqueous granulation, aqueous granulation and direct compression. 
The tablets prepared by these three methods were evaluated for different parameters such as 
average weight, hardness, carr’s index, tapped density, friability, disintegration, content 
uniformity test and in vitro dissolution test. All the parameters were found within the 
specification. The assay values are within the limit of 90% to 110%. The dissolution profile 
revealed that tablets prepared by direct compression method showed faster dissolution rate 
compared to other batches and marketed product. Hence it can be concluded that chewable 
tablets of Mebendazole could be prepared by direct compression fulfilled all the criteria for 
chewable tablets. 
 
Rohan A Khutale et al., (2015)54 developed chewable tablets of Ibuprofen by using novel 
coprocessed excipient consisting of dicalcium phosphate and magnesium stearate, in different 
ratios. The developed excipients were evaluated for angle of repose, cars index and hausner’s 
ratio in comparison with physical mixture of excipient. The angle of repose of developed 
excipient was found to be less than 20°, cars index 10-20% and hausners ratio in the range of 
1.10 -1.17. Chewable tablets of Ibuprofen were also evaluated for various post compression 
parameters. Short term stability study (at 400C/75%RH for 3 months), drug excipients 
interactions (IR, DSC) were also studied. Among the designed formulations, the formulation 
(B1) containing (21:0.5 mixture of dicalcium phosphate and magnesium stearate) emerged as 
the overall best formulation, based on drug release compared to other formulation.  
 
Pankaj P Amrutkar et al., (2010)55 developed taste masked chewable dispersible tablets of 
Lamotrigine by complexation with Precirol ATO-05. These tablets can be swallowed in the form 
of dispersion; hence it is suitable dosage form for paediatric and geriatric patients. Drug - Precirol 
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ATO-05 was prepared in ratio of 1:0.5, 1:1, 1:1.5 and 1:2. The prepared tablets were evaluated 
for general appearance, content uniformity, hardness, friability, taste evaluation, mouth feel, in 
vitro disintegration time and in vitro dissolution studies. Tablets with Precirol ATO-05 have 
shown good disintegrating features, also the dispersion not shown any bitter taste indicate the 
capability of Precirol ATO-05 used both as disintegrant and taste masking agent. Almost more 
than 90 percent of drug was released from the formulation within 1 h. Further formulations were 
subjected to stability testing for 3 months at 25±5ºC/60±5%RH; 30±5ºC/65±5%RH and 
40±5ºC/75±5%RH. Tablets have shown no appreciable changes with respect to taste, 
disintegration, dissolution profiles and the study concludeds stable Lamotrigine dispersible tablets 
could be successfully prepared by complexing with Precirol ATO-05. 
 
Vijaykumar Ghorwade et al., (2011)56 prepared Montelukast sodium fast dissolving films 
by solvent casting method using HPMC as film base with different concentrations of 
superdisintegrants like microcrystalline cellulose and crospovidone and using PEG 400 as 
plasticizer. The physicochemical parameters of the fast dissolving films were evaluated. The 
compatibility of the drug in the formulation was confirmed by IR and DSC studies. Scanning 
electron microscopy revealed the morphology of the films.  In vitro dissolution studies and 
mechanism of drug release was identified. The formulation F2 and F5 with 4% of 
crospovidone and 10% MCC respectively showed a maximum cumulative percentage drug 
release of 97.42% and 94.64% at the end of 30 min. The release of drug from the films has 
followed first-order kinetics. No significant change in the physical parameters, in vitro 
disintegration time and drug content of F2 was observed during storage at 40±20C/75±5% 
RH for 3 months. Hence it can be concluded that 4% crospovidone and 10% MCC with 4% 
HPMC as a film base was suitable for developing fast dissolving films of Montelukast 
sodium. 
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CHAPTER- 3 
AIM AND PLAN OF WORK 
3.1 AIM AND OBJECTIVE OF THE WORK 
 The aim of present study is to formulate sugar free Montelukast sodium chewable 
tablets using various disintegrants and superdisintegrants by direct compression method and 
to evaluate the formulations for various pharmaceutical parameters and compare with 
marketed product of Montelukast sodium chewable tablets. 
 Montelukast sodium is used for chronic treatment of asthma and allergic rhinitis.  
Paediatric, geriatric and bedridden patients show inconvenience in swallowing conventional 
tablets of Montelukast sodium with lesser amounts of water.  
  Montelukast sodium is basically a tasteless drug. So some patient’s does not like to 
consume the drug orally. Moreover, marketed preparation of Montelukast sodium currently 
available is not completely devoid of tasteless problem.  
 So the objective of the study is to produce a drug delivery system with better 
pharmaceutical and therapeutic properties and making the formulation suitable for diabetic 
and non diabetic patients and minimizing the drawbacks of commercially available 
conventional Montelukast sodium tablets by formulating sugar free Montelukast sodium 
chewable tablets thereby improving the patient compliance, convenience in administration 
and better mouth feel. Also the effectiveness of Montelukast sodium will be improved by the 
reduction in size that occurs during mastication of drug before swallowing. 
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3.2 PLAN OF WORK 
The present work was carried out to formulate sugar free Montelukast sodium chewable 
tablets and to evaluate the tablets for various pharmaceutical parameters. It was planned to 
carry out this work as outlined below. 
 To carry out the preformulation studies of API such as 
 Organoleptic properties 
 Solubility 
 Drug excipients compatibility study  
 To carry out the drug - excipients interaction studies by FT- IR Spectrophotometer. 
 To carry out precompression parameters such as 
 Angle of repose 
 Bulk density 
 Tapped density 
 Compressibility index 
 Hausner’ s ratio 
  To formulate sugar free chewable tablets of Montelukast sodium by “Direct compression     
 method”. 
 To evaluate the compressed tablets for following parameters 
 Thickness 
 Hardness 
 Friability 
 Weight variation 
 Wetting time 
 Water absorption ratio 
 Taste evaluation 
 Disintegration time 
 Assay  
 In vitro dissolution studies 
 
 To perform stability study for the optimized formulation at 25±20C/60%±5%RH and 
40±20C/75%±5%RH for three months. 
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CHAPTER - 4 
MATERIALS AND METHODS 
4.1 LIST OF MATERIALS USED AND MANUFACTURERS 
Table 2: List of Materials used and Manufacturers 
S. No. MATERIALS MANUFACTURERS 
1 Montelukast sodium   MetroChem API Pvt. Ltd., Hyderabad, Telangana. 
2 Mannitol anhydrous Shandong Tunali Pharma, China. 
3 Maize starch Universal Starch Chemical Alied, Ltd., Mumbai, Maharashtra. 
4 Pregelatinized starch DFE Pharma, Cuddalore, Tamilnadu. 
5 Sodium starch glycolate Prachin Chemical Pvt. Ltd., Ahmedabad, Gujarat. 
6 Croscarmellose sodium Prachin Chemical Pvt. Ltd., Ahmedabad, Gujarat. 
7 Crospovidone Huangshan Bonsun Pharma Pvt. Ltd., China. 
8 Neo sucralose Nutra Sweet Company, Jaipur, Rajasthan. 
9 Strawberry powder flavor Ridhi Sidhi Pharmaceutical Pvt. Ltd., New Delhi. 
10 Iron oxide red Koel Colours Pvt. Ltd., Mumbai, Maharashtra. 
11 Methylparaben 
Rasula Pharmaceuticals and Fine Chemicals Pvt. Ltd., 
Hyderabad, Telangana. 
12 Propylparaben 
Rasula Pharmaceuticals and Fine Chemicals Pvt. Ltd., 
Hyderabad, Telangana. 
13 Magnesium stearate Accent Microcell Pvt. Ltd., Ahmedabad, Gujarat. 
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4.2 DRUG PROFILE57 
DRUG : Montelukast Sodium 
STRUCTURAL FORMULA       : 
                                   
M OLECULAR FORMULA : C35 H35Cl NNao3S. 
MOLECULAR   WEIGHT  608.169 g/mol. 
CHEMICAL NAME : Sodium;2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-  
yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl) 
phenyl]propyl]sulfanylmethyl]cyclopropyl]acetate. 
CATEGORY : Leukotriene receptor antagonists. 
 DOSE : 10 mg OD; Children 2-5 yr: 4mg OD, 6-14yr: 5mg OD. 
DESCRIPTION              : Off white to pale yellow coloured powder. 
SOLUBILITY :  Soluble in water, methanol and ethanol, practically       
insoluble in acetonitrile. 
 MELTING POINT               : 108-110°C. 
 
MECHANISM OF ACTION58  
 Montelukast inhibits bronchoconstriction due to antigen challenge. Montelukast is a selective 
leukotriene receptor antagonist of the cysteinyl leukotriene CysLT 1 receptor. The cysteinyl 
leukotrienes (LTC 4, LTD 4, LTE 4) are products of arachidonic acid metabolism that are 
released from various cells, including mast cells and eosinophils. They bind to cysteinyl 
leukotriene receptors (CysLT) found in the human airway. Binding of cysteinyl leukotrienes 
to leukotriene receptors has been correlated with the pathophysiology of asthma, including 
airway edema, smooth muscle contraction and altered cellular activity associated with the 
inflammatory process, factors that contribute to the signs and symptoms of asthma. 
Montelukast binding to the CysLT 1 receptor is high-affinity and selective, preferring the 
CysLT 1 receptor to other pharmacologically important airway receptors, such as the 
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prostanoid, cholinergic or beta-drenergic receptor. Montelukast inhibits physiologic actions 
of LTD 4 at the CysLT 1 receptors, without any agonist activity. 
 
Fig 2:  Potential Sites and Effects of Cysteinyl Leukotrienes 
  
 PHARMACOKINETICS59 
 Absorption:  Rapidly absorbed after oral administration with mean oral bioavailability of  
             64%. Food doesn’t affect absorption of drug.  
 Distribution: Minimally distributed to the tissues with a steady – state volume of distribution   
   of 8 to 11 L. Over 99% is bound to plasma proteins. 
 Metabolism: Extensively metabolized, but plasma levels of metabolites at therapeutic doses 
             are undetectable. In vitro studies with human liver microsomes demonstrate  
             metabolism involvement by cytochrome P-450 3A4 and 2c9. 
 Excretion:   About 86% of an oral dose is metabolized and excreted in the faeces, indicating  
           drug and its metabolites are excreted almost exclusively in the bile. Half – life is  
           2 to 5 hours. 
              
 DRUG INTERACTIONS60 
Metabolism may be increased with Rifampicin, Phenobarbitol and Phenytoin. Peripheral 
oedema may occur with Prednisone. 
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 ADVERSE REACTIONS 
 Central Nervous System    :   Head ache, dizziness, fatigue, asthenia. 
  Gastrointestinal Tract      :   Dyspepsia, infectious gastroenteritis, abdominal pain. 
 Respiratory System          :   Cough, influenza. 
 Skin            :   Rash.  
 Others            :   Fever, trauma. 
  
 INDICATIONS 
 Prophylaxis and chronic treatment of asthma, allergic rhinitis. 
 
DOSAGE AND ADMINISTRATION61 
Management of chronic asthma: 
Adult: 10 mg once daily in the evening. 
Child: 2-5 yr: 4mg daily; 6-14 yr: 5mg daily; 15 yr: 10 mg once daily.  
All doses to be taken in the evening. 
 
CONTRAINDICATIONS: 
Contraindicated in patients with hypersensitivity to drug or its components. Also 
contraindicated in patients with acute asthmatic attacks or status asthmatics. Although airway 
function is improved in patients with known aspirin hypersensitivity, these patients should 
avoid aspirin and NSAIDS. 
 
MARKETED PRODUCTS: 
Montelast (tab), Monti (tab), Romilast(tab), Romilast (oral granules), Symkast(tab),Telekast 
(tab)Zmont theo (combination tab), Lukalov-M (syrup), Levontel (syrup). 
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4.3. EXCIPIENTS PROFILE 
 4.3.1 MANNITOL62, 63 
 
NON PROPRIETARY NAMES              : BP: Mannitol. 
JP: D-Mannitol. 
PhEur: Mannitol. 
USP: Mannitol. 
SYNONYMS                       : Cordycepic acid, emprove; manna sugar; D-mannite; 
mannite; mannitolum; mannogem; Pearlitol. 
CHEMICAL NAME                                    : D-Mannitol. 
EMPIRICAL FORMULA                           : C6H14O6 
MOLECULAR STRUCTURE : 
 
MOLECULAR WEIGHT                            : 182.17 g/mol. 
MELTING POINT : 166–168°C. 
SOLUBILITY : Soluble in alkalis and practically insoluble in ether. 
DESCRIPTION                                              : Mannitol occurs as a white, odorless, crystalline powder or 
free- flowing granules. 
FUNCTIONAL CATEGORY                      : Diluent; plasticizer; sweetening agent; tablet and capsule 
diluents, tonicity agent. 
APPLICATIONS                                      : Mannitol is widely used in pharmaceutical formulations and 
food products.  Mannitol may be used in direct-compression 
tablet applications, for which the granular and spray dried 
forms are available or in wet granulations. 
STABILITY  AND  STORAGE 
CONDITIONS 
: Mannitol is stable in the dry state and in aqueous solutions. 
The bulk material should be stored in a well-closed container 
in a cool, dry place. 
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INCOMPATIBILITIES : Mannitol solution, 20% w/v or stronger, may be salted out 
by potassium chloride or sodium chloride. Precipitation has 
been reported to occur when a 25% w/v mannitol solution 
was allowed to contact plastic. 
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4.3.2 STARCH62  
 
NON PROPRIETARY 
NAMES         
: BP:  Maize starch 
JP:   Corn starch 
PhEur: Pea starch 
USP-NF: Corn starch 
SYNONYMS                                         : Amido; amidon; amilo; amylum. 
CHEMICAL NAME                                    : Starch. 
EMPIRICAL FORMULA                           : C6H10O5n 
MOLECULAR STRUCTURE : 
 
MOLECULAR WEIGHT                            : 164.1406 g/mol. 
MELTING POINT  
   
: 256°C- 286°C. 
SOLUBILITY : Practically insoluble in organic solvents. Slightly soluble to 
soluble in cold water, depending upon the degree of 
pregelatinization. 
DESCRIPTION                  : Pregelatinized starch occurs as a moderately coarse to fine, white 
to off-white colored powder. It is odorless and has a slight 
characteristic taste. 
FUNCTIONAL 
CATEGORY          
: Tablet and capsule diluent; tablet and capsule disintegrant; tablet 
binder. 
APPLICATIONS : Starch is primarily used in oral solid dosage formulations as a 
binder, diluent and disintegrant. 
STABILITY  AND  
STORAGE   CONDITIONS               
: Pregelatinized starch is a stable but hygroscopic material, which 
should be stored in a well-closed container in a cool, dry place. 
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INCOMPATIBILITIES : Starch is incompatible with strong oxidizing substance. Colored 
inclusion compounds are formed with Iodine. 
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4.3.3. SODIUM STARCH GLYCOLATE63, 64 
 
NON PROPRIETARY NAMES           
  
: BP: Sodium starch glycolate 
PhEur: Sodium starch glycolate 
USP-NF: Sodium starch glycolate 
SYNONYMS                                         : Carboxymethyl starch, sodium salt, Explosol, 
Explotab, Glycolys, Primojel, starch carboxymethyl ether. 
CHEMICAL NAME                                    : Sodium carboxymethyl starch. 
EMPIRICAL FORMULA                           : C2H4O3. 
MOLECULAR STRUCTURE : 
 
MOLECULAR WEIGHT                            : 98.033 g/mol. 
MELTING POINT  Does not melt but chars at 200°C. 
SOLUBILITY : Sparingly soluble in ethanol (95%), practically insoluble in 
water. 
DESCRIPTION                                              : Sodium starch glycolate is a white or almost white, 
hygroscopic free-flowing powder. 
FUNCTIONAL CATEGORY                     : Tablet and capsule disintegrant. 
APPLICATIONS                                          : Sodium starch glycolate is widely used in oral pharmaceuticals 
as a disintegrant in capsule and tablet formulations. It is 
commonly used in tablets prepared by either direct-
compression or wet granulation processes. 
STABILITY AND STORAGE  
CONDITIONS                         
 
: 
Tablets prepared with sodium starch glycolate have good 
storage properties. Sodium starch glycolate is stable although 
very hygroscopic, and should be stored in a well-closed 
container in order to protect it from wide variations of humidity 
and temperature, which may cause caking. 
INCOMPATIBILITIES : Sodium starch glycolate is incompatible with ascorbic acid. 
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4.3.4 CROSCARMELLOSE SODIUM65 
 
NON PROPRIETARY NAMES               : BP: Croscarmellose sodium 
JP: Croscarmellose sodium 
PhEur: Croscarmellose sodium 
USP-NF: Croscarmellose sodium 
 SYNONYMS                                         : Ac-Di-Sol, carmellosum natricum conexum, crosslinked 
carboxymethylcellulose sodium, pharmacel XL, primellose, 
solutab, vivasol. 
CHEMICAL NAME                                    : Cellulose, carboxymethyl ether, sodium salt. 
EMPIRICAL FORMULA                            : C12H30NA8O27 
MOLECULAR 
STRUCTURE                     
: 
 
MOLECULAR WEIGHT                             : 90,000-700,000. 
MELTING POINT : More than 205°C 
SOLUBILITY                                              : Insoluble in water, although croscarmellose sodium rapidly 
swells to 4–8 times its original volume on contact with water. 
Practically insoluble in acetone, ethanol and toluene.  
DESCRIPTION                                             : Croscarmellose sodium occurs as an odorless, white or 
greyish white powder. 
FUNCTIONAL CATEGORY                     : Tablet and capsule disintegrant. 
APPLICATIONS : Croscarmellose sodium is used in oral pharmaceutical 
formulations as a superdisintegrant. 
STABILITY  AND  STORAGE 
CONDITIONS 
: Croscarmellose sodium is a stable though hygroscopic 
material. A model tablet formulation prepared by direct 
compression, with croscarmellose sodium as a disintegrant, 
showed no significant difference in drug dissolution after 
storage at 38°C for 14 months. Croscarmellose sodium should 
be stored in a well-closed container in a cool, dry place. 
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INCOMPATIBILITIES : The efficacy of disintegrants, such as croscarmellose sodium, 
may be slightly reduced in tablet formulations prepared by 
either the wet-granulation or direct-compression process that 
contain hygroscopic excipients such as sorbitol. 
Croscarmellose sodium is not compatible with strong acids or 
with soluble salts of iron and some other metals such as 
aluminum, mercury, and zinc. 
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4.3.5 CROSPOVIDONE62 
 
NON PROPRIETARY 
NAMES                
: BP: Crospovidone 
PhEur: Crospovidone 
USP-NF: Crospovidone 
 SYNONYMS                                         : Crospovidonum, Crospopharm, crosslinked povidone,  
kollidon CL, kollidon CL-M 
CHEMICAL NAME                                    : Povinyl-2-pyrrolidinone homopolymer, 
1-Ethenyl-2-pyrrolidinone homopolymer. 
EMPIRICAL FORMULA                            : C6H9NO 
MOLECULAR STRUCTURE                    
  
: 
 
MOLECULAR WEIGHT                             : 40,000 g\mol. 
MELTING POINT   : 150°C 
SOLUBILITY                                              : Practically insoluble in water and most common organic 
solvents. 
DESCRIPTION       : Crospovidone is a white to creamy-white, finely divided, 
free flowing, practically tasteless, odorless or nearly 
odorless powder. 
FUNCTIONAL CATEGORY                     : Tablet disintegrant. 
APPLICATIONS : Crospovidone is a solubility enhancer. 
STABILITY AND STORAGE 
CONDITIONS 
: Since crospovidone is hygroscopic, it should be stored in 
an airtight container in a cool, dry place. 
INCOMPATIBILITIES   : Crospovidone is incompatible with most organic and 
inorganic pharmaceutical ingredients. When exposed to a 
high water level, crospovidone may form molecular adduct 
with some materials. 
 
  
CHAPTER- 4   MATERIALS AND METHODS 
 
S.B.C.P  DEPARTMENT OF PHARMACEUTICS Page 53 
  
4.3.6 NEO SUCRALOSE62, 66 
 
NON PROPRIETARY 
NAMES                
: USP-NF: Sucralose. 
 SYNONYMS                                         : Splenda, sucralose, sucralosum, sucraplus. 
CHEMICAL NAME                                    : 1,6-Dichloro-1,6-dideoxy D-fructofuranosyl-4-
chloro-4-deoxya-D-galactopyranoside . 
EMPIRICAL FORMULA                            : C12H19Cl3O8 
MOLECULAR STRUCTURE                    
  
: 
 
MOLECULAR WEIGHT                             : 397.64 g/mol. 
MELTING POINT   : 130°C. 
SOLUBILITY                                              : Freely soluble in ethanol (95%), methanol and water, 
slightly soluble in ethyl acetate. 
DESCRIPTION       : Sucralose is a white to off-white colored,     free-
flowing, crystalline powder. 
FUNCTIONAL CATEGORY : Sweetening agent. 
APPLICATIONS : Sucralose is used as a sweetening agent in beverages, 
foods and pharmaceutical applications. It has a 
sweetening power approximately 300–1000 times 
that of sucrose and has no aftertaste.  
STABILITY AND STORAGE 
CONDITIONS 
: Sucralose should be stored in a well-closed container 
in a cool, dry place, at a temperature not exceeding 
20°C. Sucralose, when heated at elevated 
temperatures, may break down with the release of 
carbon dioxide, carbon monoxide and minor 
amounts of hydrogen chloride. 
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INCOMPATIBILITIES   
 
 
: Sucralose may be contaminated with traces of heavy 
metals, which can lead to incompatibility with active 
ingredients e.g. Ascorbic acid. It may also be 
contaminated with sulfite from the refining process. 
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 4.3.7 METHYL PARABEN62 
 
 NON PROPRIETARY 
NAMES                
: BP: Methyl hydroxybenzoate 
JP: Methyl parahydroxybenzoate 
PhEur: Methyl parahydroxybenzoate 
USP-NF: Methylparaben 
 SYNONYMS                                         : 4-Hydroxybenzoic acid methyl ester, metagin. 
CHEMICAL NAME                                    : Methyl-4-hydroxybenzoate. 
EMPIRICAL FORMULA                            : C8H8O3 
MOLECULAR STRUCTURE                   
  
: 
 
MOLECULAR WEIGHT                                  
 
: 152.15 g/mol. 
MELTING POINT : 125-128°C. 
SOLUBILITY                                     : Soluble in acetone, alcohol and mineral oil, water, when heated. 
DESCRIPTION                                                :
   
Methylparaben occurs as colorless crystals or a white crystalline 
powder. It is odorless or almost odorless and has a slight burning 
taste. 
FUNCTIONAL CATEGORY  Antimicrobial preservative. 
APPLICATIONS : Methylparaben is widely used as an antimicrobial preservative in 
cosmetics, food products and pharmaceutical formulations. 
STABILITY AND STORAGE   
CONDITIONS                                                  
:
   
Aqueous solutions of methylparaben at pH 3–6 may be sterilized 
by autoclaving at 121°C for 20 minutes, without decomposition. 
Methylparaben should be stored in a well closed container in a 
cool and dry place. 
INCOMPATIBILITIES                                              
:
   
Incompatibilities with other substances, such as bentonite, 
magnesium trisilicate, talc, tragacanth, sodium alginate, essential 
oils, sorbitol and Atropine, have been reported. It also reacts 
with various sugars and related sugar alcohols. 
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4.3.8 PROPYL PARABEN62, 67 
NON PROPRIETARY NAMES               : BP: Propyl hydroxybenzoate 
JP: Propyl parahydroxybenzoate 
PhEur: Propyl parahydroxybenzoate 
USP-NF: Propylparaben. 
SYNONYMS                                         : 4-Hydroxybenzoic acid propylester, nipasol, propagin, propyl 
aseptoform, propyl butex,  propyl chemosept. 
CHEMICAL NAME                                    : Propyl 4-hydroxybenzoate. 
EMPIRICAL FORMULA                            : C10H12O3 
MOLECULAR STRUCTURE : 
 
MOLECULAR WEIGHT                                  : 180.20 g/mol. 
MELTING POINT : 96 - 99°C. 
SOLUBILITY                                     : Soluble in acetone, alcohol and mineral oil, water, when 
heated. 
DESCRIPTION                                      : Propylparaben occurs as a white, crystalline, odorless and 
tasteless powder. 
FUNCTIONAL CATEGORY                      : Antimicrobial preservative. 
APPLICATIONS                                           : Propylparaben is widely used as an antimicrobial preservative 
in cosmetics, food products and pharmaceutical formulations. 
It may be used alone, in combination with other paraben 
esters or with other antimicrobial agents. It is one of the most 
frequently used preservatives in cosmetics. 
STABILITY AND  STORAGE   
CONDITIONS                                                  
: Aqueous propylparaben solutions at pH 3-6 can be sterilized 
by autoclaving, without decomposition. At pH 3–6, aqueous 
solutions  are stable (less than 10% decomposition) for  upto 4 
years at room temperature, while solutions at pH 8 or above 
undergo rapid hydrolysis. 
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INCOMPATIBILITIES                  
 
                             
: The antimicrobial activity of propylparaben is reduced 
considerably in the presence of nonionic surfactants as a 
result of micellization. Absorption of propylparaben by 
plastics has been reported, with the amount absorbed 
dependent upon the type of plastic and the vehicle. 
Propylparaben is discolored in the presence of iron and is 
subject to hydrolysis by weak alkalis and strong acids. 
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4.3.9 IRON OXIDE RED62, 68 
 
 NON PROPRIETARY NAMES               : Iron oxides. 
SYNONYMS                                         : Anhydrous ferric oxide, anhydrous iron, ferroxide, 
hematite, pigment red, red ferric oxide, sicovit. 
CHEMICAL NAME                                    : Iron oxide red. 
EMPIRICAL FORMULA                            : Fe2O3.  
MOLECULAR STRUCTURE                    
  
: 
 
MOLECULAR WEIGHT                                  : 159.70 g\mol. 
MELTING POINT     : 1,565°C. 
SOLUBILITY                                     : Soluble in mineral acids, insoluble in water. 
DESCRIPTION : Iron oxides occur as yellow, red, black or brown powder. 
The color depends on the particle size, shape and crystal 
structure. 
FUNCTIONAL CATEGORY : Colorant. 
APPLICATIONS  : Iron oxides are widely used in cosmetics, foods and 
pharmaceutical applications as colorants and UV absorbers. 
As inorganic colorants they are becoming of increasing 
importance as a result of the limitations affecting some 
synthetic organic dyestuffs.  
STABILITY AND STORAGE   
CONDITIONS                                                 
 : Iron oxides should be stored in well-closed containers in a 
cool, dry place. 
INCOMPATIBILITIES                                               : Iron oxides incompatible with comman organic acids, 
mineral acids and oxidizing agents. 
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4.3.10 MAGNESIUM STEARATE62 
 
 NON PROPRIETARY 
NAMES                
: BP: Magnesium stearate 
JP: Magnesium stearate 
PhEur: Magnesium stearate 
USP-NF: Magnesium stearate 
 SYNONYMS                                         : Dibasic magnesium stearate, magnesium distearate, magnesium 
stearas, magnesium octadecanoate, octadecanoic acid, 
magnesium salt, stearic acid. 
CHEMICAL NAME                                    : Octadecanoic acid magnesium salt. 
EMPIRICAL FORMULA                            : C36H70MgO4 
MOLECULAR STRUCTURE : 
 
MOLECULAR WEIGHT                                  : 591.24 g\mol. 
MELTING POINT   : 88°C. 
SOLUBILITY                                     : Practically insoluble in ethanol, ether and water, slightly soluble 
in warm benzene and warm ethanol (95%). 
DESCRIPTION                                             : Magnesium stearate is a very fine, light white, precipitated or 
milled, impalpable powder having a faint odor and a 
characteristic taste. The powder is greasy to touch and readily 
adheres to the skin. 
FUNCTIONAL CATEGORY                      : Tablet and capsule lubricant. 
APPLICATIONS                                           
  
: Magnesium stearate is widely used in cosmetics, foods and 
pharmaceutical formulations. It is primarily used as a lubricant 
in capsule and tablet manufacture at concentrations between 
0.25% and 5.0% w/w. It is also used in barrier creams. 
STABILITY AND STORAGE   
CONDITIONS                                              
: Magnesium stearate is stable and should be stored in a well-
closed container in a cool, dry place. 
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INCOMPATIBILITIES                                              : Incompatible with strong acids, alkalis and iron salts. Avoid 
mixing with strong oxidizing materials. Magnesium stearate is 
also incompatible with Aspirin, some vitamins and most 
alkaloidal salts. 
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4.4. INSTRUMENTS USED AND MANUFACTURERS 
Table: 3 List of Instruments Used and Manufacturers 
S. No. Instruments Manufacturers 
1 Single pan electronic balance Sartorius AG, Germany. 
2 
12 Station D\B tooling compression 
machine 
Fluidpack, Ahmedabad. 
3 Vernier caliper Mitutoyo Corporation, Japan. 
4 Dissolution  apparatus Electro Lab India Pvt. Ltd., Mumbai. 
5 Hardness tester Campbell Electronics, Mumbai. 
6 Friability  apparatus Electro Lab India Pvt. Ltd., Mumbai. 
7 Standard sieves Jayant Scientific Industries, Mumbai. 
8 Disintegration  apparatus Electro Lab India Pvt. Ltd., Mumbai. 
9 FT-IR spectrophotometer Shimadzu, Japan. 
10 HPLC Water Corporation, USA. 
11 Stability chamber Labtop Instruments Pvt. Ltd., Mumbai. 
12 Blister packing machine Elmach packages India Pvt. Ltd., Mumbai. 
13 UV UV Spectrum-1800 
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4.5 METHODOLOGY 
 
4.5.1 PREFORMULATION STUDIES69 
After drug discovery, with a background of physical, chemical and derived powdered 
properties of the drug molecule, the drug has to be formulated in the form that can suitably be 
administered. The first phase of physico-chemical data collection on drug substances, 
evaluating potential salts thereof and excipient suitability, prior to formulation, is known as 
preformulation. Preformulation is the interface between new drug entity and formulation 
development. It also provides road map for formulation development. Preformulation 
involves the application of biopharmaceutical principles to the physico-chemical parameters 
of the drug with the goal of designing an optimum drug delivery system. Characterization of 
the drug molecule is the very important step at the preformulation phase of product 
development. Therefore, Preformulation studies are an important tool early in the 
development of both API and drug products. The interaction between the drug and the 
excipients used in the formulation are generally included in the study, resulting in intelligent 
selection of excipients. The preliminary drug degradation profiles are included in the study to 
guide the formulation of a stable product.  
 
4.5.1.1 ORGANOLEPTIC PROPERTIES 
The organoleptic properties like color, odor and taste of API were evaluated. 
a. Color: A small amount of Montelukast sodium was taken in a butter paper and 
viewed in a well – illuminated place. 
b. Taste and odor: Very less amount of Montelukast sodium was used to assess the 
taste with help of tongue as well as smelled to get odor. 
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4.5.1.2 SOLUBILITY TEST 70 
Solubility of Montelukast sodium in water, ethanol, methanol was determined by using 
sonicator at room temperature. Approximate solubility of drugs as per I.P was mentioned in 
Table 4.    
    Table: 4 Solubility Specifications  
Solubility 
Approximate Volume of Solvent in ml 
per gm of Solute 
Very soluble less than 1 
Freely soluble 1 to 10 
Soluble 10 to 30 
Sparingly soluble 30 to 100 
Slightly soluble 100 to 1000 
Very slightly soluble 1000 to 10000 
Practically insoluble More than 10000 
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4.5.1.3 DRUG - EXCIPIENTS COMPATIBILITY STUDIES 71 
Compatibility studies were performed by preparing blend of different excipients with drug 
and stored at room temperature for one month. The blends were evaluated for every 15 days 
for changes like caking, liquefaction, discoloration and odor formation. The drug excipients 
compatibility profiles were shown in Table 5.  
                                     Table: 5 Drug - Excipients Compatibility Protocol 
S. No. Drug and Excipients Ratio (Drug:Excipients) 
1. Montelukast sodium 1 
2. Montelukast sodium  +  Mannitol anhydrous 1:1 
3. Montelukast sodium  +  Maize starch 1:1 
4. Montelukast sodium  +  Pregelatinized starch 1:1 
5. Montelukast sodium  +  Sodium starch glycolate 1:1 
6. Montelukast sodium  +  Croscarmellose sodium 1:1 
7. Montelukast sodium  +  Crospovidone 1:1 
8. Montelukast sodium  +  Neo sucralose 1:1 
9. Montelukast sodium  +  Strawberry powder flavor 1:0.5 
10. Montelukast sodium  +  Iron oxide red 1:0.5 
11. Montelukast sodium  +  Methylparaben 1:1 
12. Montelukast sodium  +  Propylparaben 1:1 
13. Montelukast sodium  +  Magnesium stearate 1:1 
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4.5.2 FT – IR SPECTRAL ANALYSIS 72 
Drug – excipients mixture of 1:1 ratio were accurately weighed and compatibility of freshly 
prepared mixtures was determined by FT-IR spectroscopy. FT-IR spectra of drug, excipient 
and the physical mixture of drug and excipients were recorded on a Fourier-transform 
infrared spectrophotometer (Shimadzu FT-IR, Japan) in the range of 4500 – 400 cm−1 and 
observed for any interaction between drug and excipients. 
  
4.5.3 EVALUATION OF PRECOMPRESSION PARAMETERS 
4.5.3.1 MICROMERITIC PROPERTIES 
4.5.3.1.1 ANGLE OF REPOSE73 
The frictional forces in a loose powder or granules can be measured by the angle of repose. 
This is the maximum angle possible between the surface of a pile of powder or granules and 
the horizontal plane. 
Method:  
The angle of repose was determined by funnel method. The funnel was fixed at a particular 
height ‘h’ on a burette stand. A graph paper was placed below the funnel on the table. The 
powder blend whose angle of repose is to be determined was passed slowly through the 
funnel, until it forms a pile. Further addition of powder blend was stopped as soon as the pile 
touches the tip of the funnel. Circumference of powder blend was drawn without disturbing 
the pile and height of pile was measured. The radius of the pile “r” and height of pile “h” 
were noted. Angle of repose is determined using the following formula.  
 
  
Where,  
 θ = Angle of repose 
 h = Height of the pile 
 r = Radius of the pile 
Flow properties and corresponding angle of repose as per USP was listed in Table 6. 
  
  
    θ = tan-1 (h/r) 
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Table: 6 Flow Properties and Corresponding Angle of Repose as per USP 
S. No. Type of Flow Angle of Repose (Ɵ) 
1.  Excellent 25 – 30 
2.  Good 31 – 35 
3.  Fair 36 – 40 
4.  Passable 41- 45 
5.  Poor 46 – 55 
6.  Very poor 56 – 65 
7.  Extremely poor ˃ 66 
 
4.5.3.1.2 BULK DENSITY 74 
Accurate quantity of weighed powder blend was transferred into a 50ml measuring cylinder 
without any tapping during transfer and the volume occupied by the powder blend was 
measured. Bulk density (Db) was determined by using formula. 
 
 
Where, 
 Db = Bulk density 
 m = Mass of the blend in gm 
 v0 = Untapped volume 
 
4.5.3.1.3 TAPPED DENSITY 75 
Tapped density is determined by introducing the known quantity of powder blend into a 
graduated cylinder and the cylinder was mechanically tapped by placing on the bulk density 
apparatus. The volume was measured by tapping the powder blend for 500 times. Then the 
tapping was done for 750 times and the tapped volume was noted. The tapped density was 
calculated by using the formula. 
  
 
Where, 
 Dt = Tapped density, 
 m = Mass of blend in gm 
 vt = Tapped density 
      Db = m/ v0 
     Dt = m/vt 
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4.5.3.1.4 MEASUREMENT OF POWDER COMPRESSIBILITY 76 
A. Compressibility Index 
The word compressibility is the ability to reduce the volume under pressure. The 
compressibility index of powder blend was determined by the carr’s compressibility index. It 
is used as an indication of the flowability of a powder. A compressibility index greater than 
25 is an indication of poor flowability and below 15 indicates good flowability. 
 
 
 
 
B. Hausner’s Ratio 
The Hausner’s ratio is a number that is correlated to the flowability of a powder or granular 
material. The ideal value should be 1.2–1.5. Hausner’s ratio was determined by the ratio of 
tapped density and bulk density. The scale of flowability was shown in   Table 7. 
 
 
  
Table: 7 Scale of Flowability 
Compressibility Index (%) Flow Character Hausner’s Ratio 
01 – 10 Excellent 1.00 – 1.11 
11 – 15 Good 1.12 – 1.18 
16 – 20 Fair 1.19 – 1.25 
21 – 25 Passable 1.26 – 1.34 
26 – 31 Poor 1.35 – 1.45 
32 – 37 Very poor 1.46 – 1.59 
 
 
 
 
 
  
Compressibility index = ( ܂܉ܘܘ܍܌ ܌܍ܖܛܑܜܡି ۰ܝܔܓ ܌܍ܖܛܑܜܡ)
܂܉ܘܘ܍܌ ܌܍ܖܛܑܜܡ ×100 
  Hausner’s ratio = 
܂܉ܘܘ܍܌ ܌܍ܖܛܑܜܡ
۰ܝܔܓ ܌܍ܖܛܑܜܡ  
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4.5.4 FORMULATION OF MONTELUKAST SODIUM CHEWABLE TABLETS BY 
DIRECT COMPRESSION METHOD77 
Chewable tablets of Montelukast sodium were prepared by direct compression method as per 
the composition shown in Table 8. Five formulations (F-I to F-V) were prepared by direct 
compression method. 
 
DIRECT COMPRESSION METHOD 
Sieving 
The active ingredient was passed through the sieve # 40. The other ingredients given in the 
formulation table were passed separately through the same sieve. 
Dry mixing 
All the materials (including the active ingredient) were weighed and taken in a poly bag and 
mixed for 10 minutes. 
Lubrication  
The magnesium stearate was passed through the sieve # 60 and mixed together with the 
powder mixture in a polybag for 5 minutes to get a uniform blend. 
Compression 
Finally, the powder mixture was compressed into tablets using rotary tablet compression 
machine of punch size 7.14mm to prepare tablets each weighing 150mg. 
Packing  
The prepared tablets were packed by PVC- Alu Blister packing. 
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FORMULATION FLOW CHART OF DIRECT COMPRESSION METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
    STEPS 
  SIEVING 
DRY MIXING 
LUBRICATION 
COMPRESSION 
PACKING 
All the ingredients 
were passed through 
sieve # 40. 
Mixed for 10 minutes in    
 poly bag. 
Magnesium stearate was 
passed through sieve # 60 and 
mixed with powder blend for 5 
minutes. 
The powder mixture was 
compressed into tablets using 
rotary tablet compression 
machine of 7.14 mm punch. 
andie. 
The compressed tablets were 
packed in PVC – Alu Blister 
packing. 
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Table: 8 Composition of Montelukast sodium Chewable Tablets 
Ingredients 
Quantity per Tablet (mg) 
Formulation Code  
F-I F-II F-III F-IV F-V 
Montelukast sodium 5.00 5.00 5.00 5.00 5.00 
Mannitol anhydrous 124.20 124.20 124.20 124.20 124.20 
Maize starch 15.00 - - - - 
Pregelatinized starch - 15.00 - - - 
Sodium starch glycolate - - 15.00 - - 
Croscarmellose sodium - - - 15.00 - 
Crospovidone - - - - 15.00 
Neo sucralose 1.50 1.50 1.50 1.50 1.50 
Strawberry powder flavor 0.80 0.80 0.80 0.80 0.80 
Iron oxide red 0.20 0.20 0.20 0.20 0.20 
Methylparaben 1.50 1.50 1.50 1.50 1.50 
Propylparaben 0.30 0.30 0.30 0.30 0.30 
Magnesium stearate 1.50 1.50 1.50 1.50 1.50 
Weight of each tablet 
(mg) 
150.00 150.00 150.00 150.00 150.00 
 
  
CHAPTER- 4   MATERIALS AND METHODS 
 
S.B.C.P  DEPARTMENT OF PHARMACEUTICS Page 71 
  
4.5.5 POST COMPRESSION PARAMETERS 
The compressed tablets were evaluated for the following parameters. 
 
4.5.5.1 GENERAL APPEARANCE 
The compressed tablets were examined under a biconvex lens for surface cracks, depression 
and pinholes. 
 
 4.5.5.2 THICKNESS 78 
The diameter and punch size of tablets depends on the die and punches selected for making 
the tablets. The thickness of tablet is measured by screw gauge. Thickness values were 
expressed in millimeter. 
The thickness was measured by placing the tablet between two arms of the vernier caliper. 
Five tablets were taken and their thickness was measured. 
 
4.5.5.3 HARDNESS TEST OR CRUSHING STRENGTH79 
The tablet requires a certain amount of strength or hardness, to withstand mechanical shocks 
of handling during its manufacture, packaging and transport. In addition tablets should be 
able to withstand reasonable abuse when in the hands of the consumer. Adequate tablet 
hardness and resistance to powdering and friability are necessary requisites for consumer 
acceptance. 
Hardness of the tablet is defined as the force required in breaking a tablet in a diametric 
compression test. Hence hardness is sometimes referred to as “crushing strength”. It was 
measured using Monsanto tablet hardness tester. The values were expressed in kg/cm2. In this 
test, a tablet was placed between two anvils, force was applied to the anvils and the crushing 
strength that just causes the tablet to break is recorded.  
 
4.5.5.4 WEIGHT VARIATION TEST 80 
Weigh individually 20 tablets and calculate the average weight. Not more than two of the 
individual weights deviate from the average weight by more than the percentage deviation 
given in Table 9 and none should deviate by more than twice that percentage limit. The 
uniformity of weight and percentage deviation of tablets as per IP were presented in Table 9. 
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Table: 9 Uniformity of Weight and Percentage Deviation 
S.No. Average Weight of Tablet (mg)  Percentage Deviation (%) 
1. 130 mg or less ± 10% 
2. More than 130 mg or less than 324 mg ± 7.5% 
3. 324 mg or more ± 5% 
 
The percentage deviation of the tablets were calculated by the formula, 
 
 
 
 
4.5.5.5 FRIABILITY 81 
The friability test of tablets was determined by using Roche friabilator. Ten tablets were 
dusted and weighed on the analytical balance. The tablets were placed in the drum of the 
friability tester and rotated for 100 times at 25 RPM for 4 minutes. The tablets were de dusted 
and reweighed. The percentage friability of the tablets were calculated by the formula. 
 
  
 
 
4.5.5.6 TASTE EVALUATION (SENSORY EVALUATION) 82 
Sensory evaluation is defined as a scientific disciplines used to measure, analyze and interpret 
reaction to those characteristic of material as they are received by the senses of sight, smell, 
taste, touch and hearing. 
The taste evaluation was done by taste panels. The method chosen was ranking test and for 
this purpose 10 human volunteer was selected. The dispersion of pure drug and trial 
formulations were given to the panelists. The intensity of bitterness was asked from panelists. 
 
  
Percentage deviation =  ൫ ܅܍ܑ܏ܐܜ ܗ܎ ܜ܉܊ܔ܍ܜ (ܕ܏)ି ۯܞ܍ܚ܉܏܍ ܟ܍ܑ܏ܐܜ ܗ܎ ܜ܉܊ܔ܍ܜ (ܕ܏)൯
ۯܞ܍ܚ܉܏܍ ܟ܍ܑ܏ܐܜ ܗ܎ ܜ܉܊ܔ܍ܜ (ܕ܏)  × 100 
     Percentage Friability (%) = ۷ܖܑܜܑ܉ܔ ܟ܍ܑ܏ܐܜି۴ܑܖ܉ܔ ܟ܍ܑ܏ܐܜ
۷ܖܑܜܑ܉ܔ ܟ܍ܑ܏ܐܜ  × ૚૙૙ 
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4.5.5.7 DISINTEGRATION TIME 83 
For a drug to be absorbed from a solid dosage form after oral administration, it must first be 
in solution and the first important step towards this condition is usually the break-up of the 
tablet; a process known as disintegration.   
Place 1 tablet in each of these six tubes of the basket and one disk was added to each tube. 
Operate the disintegration apparatus using 900 ml of distilled water at 370 ± 20C. The time 
taken in seconds for complete disintegration of the tablets with no palpable mass remaining in 
the apparatus was measured.  
 
4.5.5.8 WETTING TIME AND WATER ABSORPTION RATIO 84 
A piece of tissue paper folded twice was placed in a small petridish (internal diameter = 
6.5cm) containing 6 ml of water. A preweighed tablet was placed on the surface of the paper 
and the time required for complete wetting was then measured. The time required for the 
water to reach upper surface of the tablet was noted as the wetting time. The water absorption 
ratio (R) was determined using the following equation. 
 
  
 
Where, 
         Wa - Weight of tablet before wetting. 
         Wb - Weight of tablet after wetting. 
 
4.5.5.9 ASSAY OF MONTELUKAST SODIUM BY HPLC METHOD 85 
Chromatographic Conditions             
Column : Stainless steel column 15 cm × 4.6 mm. 
Mobile phase : 22 ml buffer solution, 78 ml Methanol. 
Buffer : Dissolve 3.85 gm of ammonium acetate in 1000 ml of water and add 
1ml of triethyl amine. Adjust the pH to 5.5 with glacial acetic acid. 
Flow rate : 1.5 ml per minute. 
Injection volume : 10 µl. 
Wave length : 240 nm. 
Temperature : 40°C. 
 
  
       R = ୛ୟି୛ୠ
୛ୠ
 × 100 
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Preparation of Mobile Phase 
Buffer and Methanol were mixed in the ratio of 22:78. The pH of the mobile phase was 
adjusted to 5.5.  
Preparation of Standard Solution  
0.005% w/v solution of Montelukast reference standard in methanol. 
Preparation of Sample Solution  
20 tablets were weighed and powdered. The powder equivalent to 50mg of Montelukast was 
dissolved in methanol. 1.0 ml of this solution was diluted to 10 ml with methanol. 
Sample Injection Procedure 
10 µl of filtered sample solution and standard solution were separately injected into HPLC 
system. The chromatogram was recorded and responses were measured for major peaks. 
The content of Montelukast in the powder mixture was calculated by using the following 
equation, 
 
 
 
 
Where, 
 P = Purity of Montelukast sodium 
 Avg. Wt = Average weight in mg  
Content of Montelukast sodium =     
ௌ௔௠௣௟௘ ௔௥௘௔
ௌ௧௔௡ௗ௔௥ௗ ௔௥௘௔ × ௌ௧௔௡ௗ௔௥ௗ ௪௘௜௚௛௧ௌ௔௠௣௟௘ ௪௘௜௚௛௧ × ௉ଵ଴଴ × ܣݒ݃.ܹݐ 
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4.5.5.10 IN VITRO DISSOLUTION STUDIES 86 
Dissolution Parameters 
 Apparatus                 :      USP Dissolution apparatus, Type II (Paddle).   
  Medium                     :       900ml of distilled water with 0.5% SLS. 
  RPM                          :       50. 
  Temperature              :       37°C ± 0.5°C. 
  Sampling interval      :      5, 10, 15, 20, 25 and 30. 
  Sample withdrawn     :       5 ml. 
  Wavelength                :       350 nm. 
  Instrument                  :       UV spectrophotometer. 
 
Preparation of 0.5% Sodium lauryl sulphate Solution 
Place 5 gm of sodium lauryl sulphate into the 1000 ml volumetric flask and the volume was 
made up with de - mineralized water.   
Procedure 
The in-vitro dissolution studies of Montelukast sodium chewable tablets were performed 
using dissolution apparatus USP Type II (paddle). The volume of dissolution medium                
(distilled water with 0.5% SLS solution) used was 900 ml and the temperature was 
maintained at 37±0.5˚C. The speed of the paddle was set at 50 rpm. One tablet was placed in 
each jar of dissolution apparatus. 5ml of sample from each jar was withdrawn at every 5 
minutes interval upto 30 minutes and same volume of dissolution medium was replaced to 
each dissolution jar, so that volume of dissolution medium was maintained to 900 ml. The 
sample was filtered and diluted with dissolution medium and the amount of Montelukast 
sodium released from chewable tablets was determined spectrophotometrically at 350 nm 
using distilled water with 0.5% SLS as blank.  
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4.5.5.11 STABILITY STUDIES 87 
Stability of a pharmaceutical product may be defined as the capability of a particular 
formulation in a specific container/closure system to remain within its physical, chemical, 
microbiological, toxicological, protective and informational specifications. 
Why stability studies are necessary 88  
 Stability study plays a central role in drug development 
 Permit understanding of the molecule 
 Essential for developing analytical method 
 Essential for selecting packaging for drug substance and drug product 
 Essential for choosing storage conditions for drug substance and drug product  
 
ACCELERATED STABILITY STUDIES 89 
Generally, the observation of the rate at which the product degrades under normal room 
temperature requires a long time. To avoid the undesirable delay, the principles of accelerated 
stability studies are adopted by accelerating the parameters such as temperature, humidity and 
light. 
International Council of Harmonization (ICH) guidelines for “Stability testing of new drug 
substances for drug substance and product” (QIA) describes the stability test requirement for 
drug registration application in the European Union, Japan and United States of America. 
ICH guidelines specifies the length of study and storage conditions. 
 Accelerated testing : 40 ± 2ºC & 75 ± 5% RH for 0,1,2,3 & 6 months. 
 Long term testing   : 25 ± 2ºC & 60 ± 5% RH for 0 & 12 months. 
 
Procedure 
Stability studies were carried out for optimized formulation (F-V) at 25±2°C/60C±5%RH and 
40±2°C/75%±5%RH for 3 months. The selected clear ALU-ALU packed formulations were 
stored at 25±2°C/60C±5%RH and 40±2°C/75%±5%RH for 3 months and their physical 
appearance, average weight, thickness, hardness, friability, disintegration test, assay and in 
vitro drug release were evaluated at specified intervals of time (every month).  
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  CHAPTER- 5 
RESULTS AND DISCUSSION 
 
The present study was undertaken to formulate sugar free Montelukast sodium chewable 
tablets by direct compression method using various disintegrants and superdisintegrants. The 
substance used as disintegrants and superdisintegrants are maize starch, pregelatinized starch, 
sodium starch glycolate, croscarmellose sodium and crospovidone. A total of five 
formulations (F-I to F-V) were prepared using various disintegrants and superdisintegrants. 
The prepared blend of different formulations were evaluated for precompression parameters 
such as I.R spectral studies, angle of repose, bulk density, tapped density, compressibility 
index and hausner’s ratio. The prepared tablets were evaluated for various post compression 
parameters like appearance, thickness, hardness, weight variation, friability, disintegration 
test, wetting time, water absorption ratio, drug content, taste evaluation and in vitro 
dissolution studies. The optimized formulation was subjected for stability studies. The results 
were presented as follows in appropriate tables and figures. 
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5.1 PREFORMULATION STUDIES  
5.1.1 ORGANOLEPTIC PROPERTIES 
The organoleptic properties of Montelukast sodium was presented in Table. 10 
Table.10 Organoleptic Properties of Montelukast sodium (API) 
Tests Specification as per I.P Observation 
Color Off white to pale yellow 
color 
Off white to pale 
yellow color 
Odor Odorless Odorless 
Taste Tasteless Tasteless 
Discussion:  
The organoleptic properties like color, odor and taste of the API were evaluated. The color of 
Montelukast sodium was found to be off white to pale yellow, no characteristic odor and no 
characteristic taste was observed in the study. Montelukast sodium showed similar color, 
odor and taste as per I.P specification. 
5.1.2 SOLUBILITY TEST 
The solubility profile of Montelukast sodium was presented in Table. 11 
  Table.11 Solubility Analysis of Montelukast sodium (API) 
Raw Material ( API ) Solubility 
 
Montelukast sodium 
Soluble in water 
Freely soluble in ethanol, methanol 
Practically insoluble in acetonitrile 
Discussion:  
The solubility analysis of drug indicates that Montelukast sodium is soluble in water, freely 
soluble in ethanol and methanol and practically insoluble in organic solvents. 
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5.1.3 DRUG - EXCIPIENTS COMPATIBILITY STUDIES 
Compatibility studies were performed by preparing blend of different excipients with drug 
and stored at room temperature for one month. The blends were evaluated for every 15 days 
for changes like caking, liquefaction, discoloration and odor formation. The drug excipients 
compatibility profiles were shown in Table. 12 
Table. 12 Drug - Excipients Compatibility Studies 
S. 
No. Composition Initial Period 
After 15 
days 
After 30 
days 
1 Montelukast sodium 
Off white to 
pale yellow 
color powder 
with no 
characteristic 
odor 
*NCC NCC 
2 Montelukast sodium  +  Mannitol anhydrous NCC NCC 
3 Montelukast sodium  +  Maize starch NCC NCC 
4 Montelukast sodium  +  Pregelatinized starch NCC NCC 
5 Montelukast sodium  +  Sodium starch glycolate NCC NCC 
6 Montelukast sodium  +  Croscarmellose sodium NCC NCC 
7 Montelukast sodium  +  Crospovidone NCC NCC 
8 Montelukast sodium  +  Neo sucralose NCC NCC 
9 Montelukast sodium  +  Magnesium stearate NCC NCC 
10 Montelukast sodium  +  Methylparaben NCC NCC 
11 Montelukast sodium  +  Propylparaben NCC NCC 
12 Montelukast sodium  +  Iron oxide red Brick red color powder NCC NCC 
13 Montelukast sodium  +  Strawberry flavor 
White color 
with strawberry 
odor 
NCC NCC 
* NCC: No Characteristic Change 
Discussion: 
From the above drug excipients compatibility study, it was observed that there was no 
characteristic change found between the drug and excipients. Thus it was concluded that the 
excipients selected for the formulation were compatible with Montelukast and suitable for 
formulation development. 
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5.2 FT- IR SPECTRAL STUDIES 
FT- IR studies of the pure Montelukast sodium, disintegrant, superdisintegrant and 
combination of drug and superdisintegrants containing highest proportion were carried out to 
found any interaction between drug and excipients used in the formulation. FT- IR study was 
performed using IR spectroscopy (SHIMADZU). The I.R. Spectra of drug, disintegrants and 
superdisintegrant were shown in fig: 3 to 13 and in table 13 to 23 respectively. The 
comparison of FT- IR spectral data of drug with superdisintegrants was given in table 24. 
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Fig. 3 FT- IR Spectrum of Pure Montelukast sodium 
Table. 13 FT- IR Spectral Data of Pure Montelukast sodium 
S. No. Wave Number (cm-1) Functional Group 
1 3356 OH alcoholic group 
2 3062 C-H aromatic stretching 
3 2978 OH carboxylic  
4 1573 C=C aromatic stretching 
5 1141 C-N stretching 
6 756 C-Cl 
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Fig. 4 FT- IR Spectrum of Maize starch 
Table. 14 FT- IR Spectral Data of Maize starch 
S. No. Wave Number (cm-1) Functional Group 
1 3170 OH  stretching 
2 2931 C-H stretching 
3 1635 Carbonyl C=O stretching 
4 1330 C-H bending 
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Fig. 5 FT- IR Spectrum of Pregelatinized starch 
Table. 15 FT- IR Spectral Data of Pregelatinized starch 
S. No. Wave Number (cm-1) Functional Group 
1 3371 OH alcoholic stretching 
2 2931 C-H stretching 
3 1643 Carbonyl C= O stretching 
4 1365 C-H bending 
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Fig. 6 FT- IR Spectrum of Sodium starch glycolate 
Table. 16 FT- IR Spectral Data of Sodium starch glycolate 
S. No. Wave Number (cm-1) Functional Group 
1 3282 OH alcoholic stretching 
2 2931 C-H stretching 
3 1604 Carbonyl C=O stretching 
4 1327 C-H bending 
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Fig. 7 FT-IR Spectrum of Crospovidone 
Table. 17 FT- IR Spectral Data of Crospovidone 
S. No. Wave Number (cm-1) Functional Group 
1 2954 Alkane  C-H stretching 
2 1666 Alkane C-H bending 
3 1427 Carbonyl C=O stretching 
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Fig. 8 FT- IR Spectrum of Croscarmellose sodium 
Table. 18 FT- IR Spectral Data of Croscarmellose sodium 
S. No. Wave Number (cm-1) Functional Group 
1 3348 OH alcoholic stretching 
2 2900  C-H stretching 
3 1627 Carbonyl C=O stretching 
4 1327 C-H bending 
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Fig. 9 FT- IR Spectrum of Montelukast sodium + Maize starch 
Table. 19 FT- IR Spectral Data of Montelukast sodium + Maize starch 
S. No. Wave Number (cm-1) Functional Group 
1 3394 OH alcoholic group 
2 2931  C-H stretching 
3 1597  C=C aromatic stretching 
4 1411 C-N stretching 
5 763 C-Cl 
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Fig. 10 FT- IR Spectrum of Montelukast sodium + Pregelatinized starch 
Table. 20 FT- IR Spectral Data of Montelukast sodium + Pregelatinized starch 
S. No. Wave Number (cm-1) Functional Group 
1 3371 OH alcoholic stretching 
2 2924  OH carboxylic 
3 1597  C=C aromatic stretching 
4 1404 C-H bending 
5 1149 C-N stretching 
6 756 C- Cl 
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Fig. 11 FT- IR Spectrum of Montelukast sodium + Sodium starch glycolate 
Table. 21 FT- IR Spectral Data of Montelukast sodium + Sodium starch glycolate 
S. No. Wave Number (cm-1) Functional Group 
1 3387 OH alcoholic stretching 
2 2931  C-H stretching 
3 1597 Carbonyl C=C stretching 
4 1334 C-H bending 
5 1149 C-N stretching 
6 763 C-Cl 
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Fig. 12 FT- IR Spectrum of Montelukast sodium + Crospovidone 
Table. 22 FT- IR Spectral Data of Montelukast sodium + Crospovidone 
S. No. Wave Number (cm-1) Functional Group 
1 3441 OH alcoholic stretching 
2 2931 C-H stretching 
3 1597 C=C alcoholic 
4 1334 C=O carbonyl stretching 
5 1165 C-N stretching 
6 756 C-Cl 
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Fig. 13 FT- IR Spectrum of Montelukast sodium + Croscarmellose sodium 
Table. 23 FT- IR Spectral Data of Montelukast sodium + Croscarmellose sodium 
S. No. Wave Number (cm-1) Functional Group 
1 3394 OH alcoholic stretching 
2 2916  C- H stretching 
3 1627  Carbonyl C=C stretching  
4 1342 C-H bending 
5 1126 C-N stretching 
6 756 C-Cl 
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Table. 24 Comparative FT- IR Spectral Data of Drug, Disintegrants and Super 
disintegrants 
Compounds 
Functional Groups (cm-1) 
OH C-H C=C C-N  C-Cl  
Drug (Montelukast sodium) 3356 3062 1573 1141 756 
Drug+ Maize starch 3394 2931 1597 1411 763 
Drug  + Pregelatinized starch 3371 2924 1597 1149 756 
Drug+Sodium starch glycolate 3387 2931 1597 1149 763 
Drug+Croscarmellose sodium 3394 2916 1627 1126 756 
Drug+Crospovidone 3441 2931 1597 1165 756 
 
Discussion: 
FT- IR spectral studies indicated that the drug is compatible with all the excipients. The FT- 
IR spectrum of physical mixture showed all the characteristic peaks of Montelukast sodium, 
thus conforming that no interaction of drug occurred with the components of formulation. 
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5.3 EVALUATION OF PRECOMPRESSION PARAMETERS 
5.3.1 MICROMERITIC PROPERTIES 
 The powder blends were evaluated for the following parameters such as angle of 
repose, bulk density, tapped density, compressibility index and hausner’ ratio. The results 
were given below in Table. 25 
Table. 25 Precompression Parameters 
Formulation 
Code 
 
Angleof 
Repose 
(Ɵ) 
Bulk 
Density  
(g/cm3) 
Tapped 
Density  
(g/cm3) 
Compressibility 
Index (%) 
Hausner’s 
Ratio 
F-I  29.3±0.1 0.305±0.2 0.361±0.2 16.2±0.2 1.18±0.2 
F-II 27.1±0.4 0.309±0.6 0.357±0.3 16.0±0.9 1.18±0.7 
F-III 27.0±0.1 0.303±0.5 0.354±0.1 15.5±0.4 1.19±0.5 
F-IV  26.5±0.9 0.292±0.7 0.367±0.8 16.3±0.7 1.17±0.2 
F-V 25.6±0.8 0.304±0.4 0.342±0.5 15.4±0.2 1.17±0.3 
All the values are expressed as mean ± SD, n=3 
 
Discussion: 
The angle of repose of all formulations were found between 250.60’ to 290.30’ that is well 
within the specification limit of 250- 290 which indicates the flow type of powder blend was 
excellent. Formulation F-V showed better flow property.  
The bulk density was found between 0.292 to 0.309 g/cm3, tapped density was found between 
0.342 to 0.367 g/cm3. Compressibility index was found in the range of 15.4 to 16.3% which 
indicates the flow type of powder blend was fair. Hausner’s ratio ranges between 1.17to 1.19. 
The above results in terms of micromeritic properties revealed that the flow property of all 
formulation was excellent and within the acceptable limit. 
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5.4 EVALUATION OF MONTELUKAST SODIUM CHEWABLE TABLETS 
5.4.1 POST COMPRESSION PARAMETERS 
5.4.1.1 GENERAL APPEARANCE 
The general appearance of all formulations (F-I to F-V) were examined and found as follows, 
Color - Brick red color 
Shape - Round 
Surface - Smooth 
Cracks, depressions, pinholes – Absent 
The prepared tablets were evaluated for various post compression parameters. The results are 
presented in Table. 26 
Table. 26 Post Compression Parameters 
Formulation  
code 
Thickness 
(mm) 
Hardness 
(kg /cm2) 
Weight 
Variation (mg) 
Friability 
(%) 
F-I 3.22±0.018 6.05±0.21 153.60±1.82 0.011±0.006 
F-II 3.20±0.032 6.42±0.14 149.20±1.59 0.012±0.008 
F-III 3.21±0.027 6.20±0.56 155.10±1.42 0.012±0.004 
F-IV 3.20±0.041 6.65±0.17 151.90±1.78 0.014±0.009 
F-V 3.22±0.032 6.15±0.56 150.80±1.29 0.013±0.012 
Marketed Sample 2.81±0.16 7.00±0.1 153.01±2.32 0.012±0.05 
All the values are expressed as mean± SD, n=3 
 
Discussion: 
Thickness and Hardness 
The thickness of tablets was measured and were found in the range between 3.20±0.032 mm 
to 3.22±0.032 mm. All the formulation possessed uniform thickness. The hardness of the 
tablets was measured and the values were found in the range between 6.05±0.21 kg/cm2 to 
6.65±0.17 kg/cm2. The prepared tablets possessed good mechanical strength with sufficient 
hardness. The thickness and hardness of marketed sample was found to be 2.81±0.16 mm and 
7.00±0.1 kg/cm2 respectively. 
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Weight Variation and Friability Test 
All formulations of Montelukast sodium chewable tablets passed the weight variation test 
since the values are within the acceptable variation limit (±7.5%) of the tablet. Similarly 
percentage friability values of the prepared Montelukast sodium chewable tablets showed less 
than 1% weight loss that is highly within the acceptable limit. Hence all the tablets passed the 
friability test. Montelukast sodium chewable tablets were evaluated for various parameters 
and the results are given in Table.27. 
Table. 27 Evaluation of Montelukast sodium Chewable Tablets 
Formulation 
Code 
Disintegration 
Test (min) 
Wetting 
Time (Sec) 
Water Absorption 
Ratio (%) Taste 
F-I 5.21±0.015 73±0.57 70.18±0.57 Sweet 
F-II 5.07±0.064 70±0.57 86.88±0.56 Sweet 
F-III 4.39±0.005 65±0.41 90.80±0.59 Sweet 
F-IV 3.23±0.057 49±.53 93.2±0.57 Sweet 
F-V 1.10±0.01 30±0.54 96.80±0.58 Sweet 
Marketed 
Sample 2.42±0.025 39±0.43 92.14±0.57 Sweet 
     All the values are expressed as mean± SD, n=3 
Discussion: 
Disintegration Time 
Disintegration time of Montelukast sodium chewable tablets were found between 1.10±0.01 
to 5.21±0.015 minutes. Specification limit of disintegration time for uncoated tablet from I.P 
is NMT 15 minutes. Disintegration time of all formulations were found within the time as 
specified in the I.P and passed the disintegration test. The disintegration time of formulation-
V containing crospovidone showed rapid disintegration (1.10±0.01 min) compared with other 
formulations.  
Wetting Time and Water Absorption Ratio  
Wetting time of all formulations were found between 30 to 73 seconds.  Formulation V 
showed least wetting time (30 sec). Formulation V containing superdisintegrant such as 
crospovidone will quickly absorb water. Water absorption ratio of all formulations were 
found between 70% to 96%. The wetting time profiles of Montelukast sodium chewable 
tablets were shown in Fig. 14 
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Fig. 14 Wetting Time Profiles of Montelukast Chewable Tablets 
 
Taste (Sensory Evaluation) 
Tasteless of the drug was changed in all formulations by using sugar free sweetening agent. 
All the formulations possessed sweet taste.  
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5.5 ASSAY  
The assay was carried out according to the procedure given in methodology. The peak area 
plot of Montelukast sodium standard was given in Fig.15 and peak area plots of Montelukast 
sodium (Formulation F-I to F-V) were given in Fig.16 to 20 and the content of Montelukast 
sodium in chewable tablets were presented in Table. 28. 
 
S. No. Name RT* Area Plate count Symmetry 
1 
Montelukast 
sodium 
2.971 6644957 4012 0.90 
       *RT- Retention Time 
Fig.15 HPLC CHROMATOGRAM OF MONTELUKAST SODIUM (Standard) 
 
  
S. No. Name RT* Area Plate count Symmetry 
1 F-I 2.970 6617882 4393 0.91 
*RT- Retention Time 
Fig.16 HPLC CHROMATOGRAM OF FORMULATION F - I 
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S. No. Name RT* Area Plate count Symmetry 
1 F-II 2.970 6639243 4105 0.91 
*RT- Retention Time 
Fig.17 HPLC CHROMATOGRAM OF FORMULATION F - II 
 
  
 
S. No. Name RT* Area Plate count Symmetry 
1 F- III 2.969 6644279 4197 0.90 
      *RT- Retention Time 
Fig.18 HPLC CHROMATOGRAM OF FORMULATION F - III 
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S. No. Name RT* Area Plate count Symmetry 
1 F-IV 2.970 6647313 4092 0.90 
     *RT- Retention Time 
Fig.19 HPLC CHROMATOGRAM OF FORMULATION F - IV 
 
 
S. No. Name RT* Area Plate count Symmetry 
1 F-V 2.971 6644957 4012 0.90 
     *RT- Retention Time 
Fig.20 HPLC CHROMATOGRAM OF FORMULATION F - V 
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Table.28 Assay of Montelukast sodium Chewable Tablets 
Formulation Code Limit(%) Assay(%) 
F-I 
90-110% 
100.70±1.50 
F-II 100.53±1.45 
F-III 100.89±2.86 
F-IV 101.52±1.24 
F-V 102.08±1.45 
Marketed sample 100.70±1.50 
 
Discussion: 
The content of Montelukast sodium is the chewable tablets were found in the range between 
100.53 to 102.08%.  The acceptable limit of Montelukast content as per I.P is 90 to 110%. 
The results revealed that the content of Montelukast sodium was within the acceptable limits 
in all the formulations. 
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5.6. CALIBRATION CURVE OF MONTELUKAST SODIUM 
 
Preparation of 0.5% of Sodium lauryl sulphate Solution90 
Place 0. 5 gm of sodium lauryl sulphate into a 100 ml volumetric flask and the volume was 
made up with de- mineralized water. 
 
Calibration Curve of Montelukast sodium 
0.025 gm of Montelukast sodium was accurately weighed and dissolved first in methanol and 
the volume was made upto 50 ml with de-mineralized water. From this 10ml was pipetted out 
and transferred into a 50 ml volumetric flask and make upto required volume using 0.5% SLS 
solution. This is secondary stock solution and from this various concentration of drug (5-50 
µg/ml) were pipetted out separately into 10 ml standard flask and make upto required volume 
using 0.5% SLS solution and the absorbance of the resulting solutions were measured by 
using UV spectrophotometer at 350 nm. Standard curve of Montelukast sodium was given in 
the table.29 and fig.21 
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Table.29 Calibration Curve Data of Montelukast sodium 
S. No. Concentration (µg/ml) Absorbance (350 nm) 
1 5 0.0812 
2 10 0.158 
3 15 0.251 
4 20 0.294 
5 25 0.401 
6 30 0.481 
7 35 0.548 
8 40 0.621 
9 45 0.705 
10 50 0.81 
 
  
  
Fig. 21 Standard Curve of Montelukast sodium 
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5.7. IN VITRO DISSOLUTION STUDIES 
The in vitro drug release studies of Montelukast sodium chewable tablets were given Table. 
30 and fig: 22 respectively. 
Table. 30 In Vitro Drug Release Data of Montelukast sodium Chewable Tablets 
Time 
(min.) 
Percentage Drug Release (%) 
F – I F – II F - III F – IV F – V 
5 10.44±0.46 15.23±1.0 29.11±0.10 32.78±1.14 39.99±0.56 
10 17.78±0.30 27.67±0.58 33.97±0.45 42.11±0.57 48.55±0.59 
15 22.77±0.54 34.23±0.59 59.45±0.01 63.12±0.05 78.45±0.64 
20 46.46±0.80 56.56±1.00 67.84±0.58 78.55±1.07 87.92±0.88 
25 62.51±1.51 69.45±1.40 84.09±0.59 88.57±0.57 94.65±1.00 
30 67.07±0.45 72.66±0.98 89.15±0.01 90.13±0.99 97.29±0.99 
All the values are expressed as mean± SD, n=3 
 
Fig. 22 In Vitro Drug Release Profiles of Montelukast sodium Chewable Tablets 
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Discussion: 
Montelukast sodium chewable tablets was prepared by direct compression method using 
disintegrants like maize starch, pregelatinized starch and superdisintegrants like sodium 
starch glycolate, croscarmellose sodium and crospovidone. The dissolution study results are 
shown in table.30. 
Montelukast sodium release was studied in 0.5% SLS solution for upto 30 minutes. The drug 
release of formulation F-I, F-II was found to be 67.07±0.45% and 72.66±0.98% at 30 
minutes. The drug release of formulation F-III, F-IV and F-V was found to be 89.15±0.01%, 
90.13±0.99% and 97.29±0.99% respectively. The acceptable in vitro dissolution limit for 
Montelukast sodium as per IP is NLT 80% of drug release at 30 minutes.  Formulations F-III, 
F-IV and F-V passed the in vitro drug release studies.  
Among the three formulations, formulation F-V containing crospovidone as superdisintegrant 
showed highest dissolution rates at the end of 30 minutes. They may be due to easy swelling 
ability and wicking capacity of crospovidone when compared to other disintegrants.  The 
order of enhancement of the dissolution rate with various disintegrants and superdisintegrants 
was found to be crospovidone ˃ croscarmellose sodium ˃ sodium starch glycolate ˃ 
pregelatinized starch ˃ maize starch. Formulation F-V was taken as optimized formulation 
based on rapid disintegration time (1.10 minute), wetting time (30 sec) and in vitro 
dissolution profiles (97.29 %). 
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5.7.1 COMPARATIVE DISSOLUTION STUDY OF MARKETED FORMULATION 
AND OPTIMIZED FORMULATION (F-V) 
The dissolution profile of optimized formulation (F-V) was compared with marketed 
Montelukast sodium chewable tablet. The comparative drug release profiles are shown in     
Table. 31 and fig.23. 
Table. 31 Comparative In Vitro Release Data of Montelukast sodium Marketed Tablet 
and Optimized Formulation (F-V) 
Time 
(min.) 
Percentage Drug Release 
Formulation F-V Marketed tablet 
5 39.99±0.56 30.09±0.11 
10 48.55±0.59 43.30±0.55 
15 78.45±0.64 59.47±0.90 
20 87.92±0.88 68.33±1.01 
25 94.65±1.00 77.57±0.62 
30 97.29±0.99 88.01±0.83 
All the values are expressed as mean± SD, n=3 
 
Fig.23 Comparative In Vitro Drug Release Profiles of Montelukast sodium Marketed 
Tablet and Optimized Formulation (F-V) 
Discussion: 
The percentage drug release of Marketed sample and optimized formulation (F-V) was found 
to be 88.01±0.83 % and 97.29 ±0.99 % at 30 minutes. The drug release of optimized 
formulation of Montelukast sodium chewable tablets was found to be greater than that of 
marketed product. 
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5.8 STABILITY STUDIES 
The optimized formulation (F-V) was selected for the stability study and stored at 
25±2°C/60%±5%RH and 40±2°C/75%±5%RH for a period of three months. The tablets were 
evaluated for various parameters like physical appearance, weight variation, thickness, 
hardness, friability, disintegration time, drug content and in vitro drug release at every month 
interval. The results are presented in Table 32 and 33. 
Table. 32 Stability Data of Optimized Formulation (F-V) Stored at 25±2°C/60%±5%RH 
S. 
No. 
Storage Conditions: 25±2°C/60%±5%RH 
Parameters Initial Period 
1st 
Month 
2nd 
Month 
3rd 
Month 
1 Physical appearance 
Brick red, round 
shaped tablets 
Complies Complies Complies 
2 Weight variation test  (mg) 150.8 150.74 150.63 150.21 
3 Thickness (mm) 3.22 3.22 3.2 3.2 
4 Hardness (Kg/cm2) 6.15 6.15 6.15 6.1 
5 Friability (%) 0.12 0.16 0.26 0.31 
6 Disintegration time (min.) 1.10 1.21 1.45 1.47 
7 
Drug content Limit (90-
110%) 
102.08 102.06 102.06 102.04 
8 
In vitro drug release at the 
end of 30 min. (%) 
97.29 97.25 97.21 97.2 
 
  
CHAPTER – 5  RESULTS AND DISCUSSION 
 
S.B.C.P DEPARTMENT OF PHARMACEUTICS Page107 
 
Table. 33 Stability Data of Optimized Formulation (F-V) Stored at 40±2°C/75%±5%RH 
S. No. 
Storage Conditions: 40±2°C/75%±5%RH 
Parameters Initial Period 
1st 
Month 
2nd 
Month 
3rd 
Month 
1 Physical appearance 
Brick red, round 
shaped tablets 
Complies Complies Complies 
2 
Weight variation test  
(mg) 
150.8 150.99 150.87 150.21 
3 Thickness (mm) 3.22 3.19 3.22 3.21 
4 Hardness (Kg/cm2) 6.15 6.15 6.17 6.17 
5 Friability (%) 0.12 0.2 0.24 0.3 
6 
Disintegration time 
(min.) 
1.10 1.21 1.45 1.00 
7 
Drug content Limit 
(90-110%) 
102.08 102.05 102.05 102 
8 
In vitro drug release 
at the end of 30 min. 
(%) 
97.29 97.22 97.18 97.11 
 
Discussion: 
Stability results revealed that there were no significant changes found in physical appearance, 
weight, thickness, hardness, friability, disintegration time, drug content and in vitro drug 
release during the period of 3 months even after stored at 25±2°C/60%±5%RH and 
40±2°C/75%±5%RH. The results revealed that the drug was stable even after stored at 
25±2°C/60%±5%RH and 40±2°C/75%±5%RH for three months. 
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CHAPTER-6 
SUMMARY AND CONCLUSION 
The present study was undertaken to formulate sugar free Montelukast sodium chewable 
tablets by direct compression method using various disintegrants and superdisintegrants. The 
substance used as disintegrants and superdisintegrants are maize starch, pregelatinized starch, 
sodium starch glycolate, croscarmellose sodium and crospovidone.   
A total of five formulations (F-I to F-V) of sugar free Montelukast sodium chewable tablets 
were prepared by direct compression method. All the formulations were evaluated for both               
pre compression and post compression parameters as per the requirements of standards. 
Preformulation study of API such as organoleptic properties, solubility, compatibility study 
and FT- IR drug - excipients interaction study were carried out. The prepared blends were 
also evaluated for precompression parameters such as angle of repose, bulk density, tapped 
density, compressibility index and hausner’s ratio. The prepared tablets were evaluated for 
post compression parameters such as thickness, hardness, weight variation, friability, 
disintegration, wetting time, water absorption ratio, taste evaluation, assay and in vitro drug 
release study. 
From the experimental results the following points can be summarized, 
 In the preformulation study Montelukast sodium showed similar color, taste and odor 
as per the I.P specification. The results of drug excipients compatibility study showed 
that the excipients selected for the formulation were compatible with the API and 
suitable for formulation development. 
 FT- IR spectral studies of pure drug and drug with excipients showed that there was 
no interaction between the drug and excipients used in the formulation. 
 The results of micromeritic properties indicate that the flow property of formulation   
F-V showed better flow property compared with other formulations. 
 All formulations possessed uniform thickness. The prepared tablets also possessed 
good mechanical strength with sufficient hardness. 
 All formulations of Montelukast sodium chewable tablets passed the weight variation 
test since the values are within the acceptable variation limit (±7.5) of the tablet. All 
formulations of Montelukast sodium chewable tablets showed less than 1% weight 
loss and passed the friability test.  
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 Disintegration time of Montelukast sodium chewable tablets were found between 
1.10±0.01 to 5.21±0.015 minutes. Formulation F- V showed least disintegration time 
(1.10±0.01 min) compared with all other formulations. 
 Wetting time and water absorption ratio of Montelukast sodium chewable tablets were 
found to be in the range between 30 to 73 seconds and 70% to 96% respectively. 
Formulation F-V prepared using crospovidone as superdisintegrant showed least 
wetting time (30±0.54 sec) and high water absorption ratio (96.80±0.58%) among all 
formulation. All formulations showed good taste and better mouth feel. 
 The content of Montelukast sodium in chewable tablets were found within the 
acceptable limits. (90-110%). 
 In the in vitro drug release study, formulation F-V prepared using crospovidone as 
superdisintegrant showed maximum drug release (97.29%) at the end of 30 minutes. 
 The obtained data suggested that formulation (F-V) containing  crospovidone as super 
disintegrant showed better disintegration time(1.10±0.01 min), wetting time 
(30±0.54sec)  and in vitro drug release (97.29%) and hence formulation F-V was 
considered as the optimized formulation based on rapid disintegration time ,wetting 
time and in vitro drug release.  
 Comparative dissolution study of optimized formulation (F-V) and marketed product 
was carried out and the drug release of optimized formulation (F-V) was rapid 
(97.29%) compared to the marketed product (88.01%) at the end of 30 minutes. From 
the results it was concluded that the formulation F-V showed rapid drug release 
compared to the marketed product. 
 The stability results of optimized formulation (F-V) indicated that there were no 
significant changes found in physical appearance, thickness, hardness, average 
weight, friability, disintegration, assay and in vitro drug release even after stored at 
25±2°C/60%±5%RH and 40±2°C/75%±5%RH for 3 months. The results showed that 
the optimized formulation F-V was stable even after stored at 25±2°C/60%±5%RH 
and 40±2°C/75%±5%RH for a period of three months. 
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CONCLUSION 
From this study, the overall results revealed that the formulation F-V containing 
crospovidone as superdisintegrant was found to be better one which satisfied all the 
criteria for chewable tablets.  The work concludes that Montelukast sodium chewable 
tablets could be successfully formulated by direct compression method using 
crospovidone as superdisintegrant which may improve the patient compliance, 
convenience in administration, therapeutic efficiency, better mouth feel making the 
formulation suitable for geriatric, bed ridden, diabetic and non diabetic patients. 
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CHAPTER-7 
FUTURE STUDY 
 
 Biopharmaceutical evaluation like in vivo study (Anti-histamine activity) can be 
performed in animals according to the guidelines approved by the “Committee of Purpose 
of Control and Supervision of Experiments on Animals (CPCSEA)”. Ministry of social 
Justice and Empowerment, Government of India. 
 Montelukast sodium tablet formulations may be evaluated for various Pharmacokinetic 
Parameters. 
 The finding of the present study has initiated the company to go for scale up trial. 
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